Anti-TMPRSS6 antibody and its uses

Abstract

Provided are antibodies and antigen-binding fragments thereof that bind to type II transmembrane serine protease 6 (TMPRSS6) on the cell surface and increase hepcidin expression, as well as methods for treating iron metabolism disorders using anti-TMPRSS6 antibodies and fragments.

Description

Related Applications

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 006,695, entitled "Anti-TMPRSS6 Antibodies and Uses Thereof," filed April 7, 2020, and U.S. Provisional Application No. 63 / 158,265, entitled "Anti-TMPRSS6 Antibodies and Uses Thereof," filed March 8, 2021, the contents of each of which are incorporated herein by reference in their entirety. [Sequence table]

[0002] This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated by reference in its entirety. The ASCII copy, created on March 29, 2021, is named 1121_101PCT_SL.txt and is 132,677 bytes in size. [Technical Field]

[0003] The present disclosure relates to antibodies and antigen-binding fragments that bind to TMPRSS6, and to the treatment of iron metabolism disorders using antibodies and antigen-binding fragments that bind to TMPRSS6. [Background technology]

[0004] Type II transmembrane serine protease 6 (TMPRSS6) is encoded by the TMPRSS6 gene and is primarily expressed in the liver. The structure of TMPRSS6 contains a type II transmembrane domain, a sea urchin sperm protein, enteropeptidase, and agrin (SEA) domain, two complement factor C1r / C1s, a sea urchin embryonic growth factor and bone morphogenetic protein (CUB) domain, and a stem region containing three low-density lipoprotein receptor (LDLR) class A repeats, as well as a C-terminal trypsin-like serine protease domain (Wang, C.-Y. et al., Front. Pharmacol. .2014.5:114). Other names for TMPRSS6 (EC3.4.21) include matriptase-2; transmembrane protease serine 6; membrane-bound mosaic serine proteinase matriptase-2; and MT2.

[0005] TMPRSS6 plays a key role in iron homeostasis through the BMP-SMAD signaling pathway, which regulates the expression of hepcidin, a hormone that controls iron absorption and mobilization from iron stores. Hepcidin (also known as hepcidin antimicrobial protein or peptide (HAMP) in humans and nonhuman primates and HAMP in mice and rats) regulates whole-body iron homeostasis by controlling the functional activity of ferroportin, the only iron efflux channel. Hepcidin binds to ferroportin and causes its internalization and degradation, thereby preventing intestinal iron absorption and release from iron stores, thereby reducing plasma iron concentrations. Chronically elevated hepcidin levels lead to systemic iron deficiency, while hepcidin deficiency leads to systemic iron overload.

[0006] TMPRSS6 negatively regulates hepcidin production and suppresses HAMP activation through a transmembrane signaling pathway triggered by iron deficiency (Du, X. et al., Science 2008.320:1088-1092; Wang, C.-Y. et al., Front. Pharmacol . 2014.5:114). A decrease in blood iron concentration activates this pathway, leading to a decrease in hepcidin production, which allows dietary iron to be absorbed from the intestine and transported from storage sites into the bloodstream. In rats with acute iron deficiency, hepatic TMPRSS6 protein levels are elevated, and hepcidin expression and production are suppressed (Wang, C.-Y. et al., Front. Pharmacol .Mutations in the entire TMPRSS6 molecule, especially in the extracellular domain, have been identified in subjects with iron deficiency anemia, particularly iron-refractory iron deficiency anemia (IRIDA), which does not respond to oral iron therapy but only partially responds to parenteral iron therapy (Wang, C.-Y. et al., Front. Pharmacol. . 2014.5:114). Loss-of-function mutations in human TMPRSS6 cause elevated hepcidin levels and iron deficiency anemia due to excessive hepcidin production, which leads to abnormal iron absorption and utilization (Camaschella, C., N Engl Journal Med 2013.168:24).

[0007] Iron overload occurs when excess iron accumulates in tissues and organs, impairing their normal function. Iron poisoning is a common complication of iron overload, resulting in high mortality rates due to iron accumulation in major organs. β-thalassemia is a disease in which HBB gene mutations result in reduced or absent β-globin (beta-globin) production, leading to erythroblast apoptosis and a lack of mature red blood cells. This leads to impaired erythropoiesis, anemia, and iron overload due to excessive iron absorption. In β-thalassemia patients, hepcidin is abnormally suppressed depending on the patient's iron loading status, resulting in hepcidin deficiency, excessive iron absorption, and the progression of systemic iron overload. Ineffective hemoglobin syndromes such as myelodysplastic syndromes (MDS), dyshematopoietic anemia, and sideroblastic anemia are also characterized by iron overload due to decreased hepcidin. Hemochromatosis (including type 1 hemochromatosis and hereditary hemochromatosis) is an iron overload disorder characterized by excessive intestinal absorption of dietary iron and a pathological increase in total body iron stores. Current standard treatments for iron overload include transfusions for ineffective hematopoiesis, which can further exacerbate iron overload, iron chelation, which leads to poor patient compliance, and phlebotomy and splenectomy to manage symptoms. Therapeutic approaches currently under development include gene therapy targeting the HBB gene, gene therapy and gene editing targeting other related genes, hepcidin mimetics, Fc fusion proteins targeting TGF superfamily ligands and inhibiting SMAD signaling, antisense RNA agents targeting TMPRSS6 (e.g., El-Beshlawy A., et al., Blood Cells, Molecules and Diseases 2019.76:53-58), and iRNA agents targeting TMPRSS6. Summary of the Invention

[0008] The present invention relates to novel antibodies and antigen-binding fragments thereof that bind to TMPRSS6, as well as methods for producing and using antibodies and antigen-binding fragments thereof that bind to TMPRSS6.

[0009] The present disclosure provides anti-TMPRSS6 antibodies, nucleic acids encoding anti-TMPRSS6 antibodies, and methods for making and using anti-TMPRSS6 antibodies. The anti-TMPRSS6 antibodies disclosed in the present disclosure include anti-TMPRSS6 antibodies and fragments thereof that can bind to TMPRSS6. The anti-TMPRSS6 antibodies disclosed in the present disclosure can bind to human TMPRSS6 on the surface of cells that express human TMPRSS6. The present disclosure provides anti-TMPRSS6 antibodies for therapeutic and diagnostic uses. The anti-TMPRSS6 antibodies disclosed in the present disclosure can be used to treat iron overload, particularly disorders of iron metabolism such as β-thalassemia, including but not limited to non-transfusion-dependent thalassemia, and other disorders of ineffective hematopoiesis.

[0010] In one aspect, an anti-TMPRSS6 antibody is provided that can bind to TMPRSS6 on the surface of a TMPRSS6-expressing cell and modulate the activity of at least one component involved in iron metabolism. The component may be a molecule or biological process related to the function of TMPRSS6. In certain embodiments, the anti-TMPRSS6 antibody disclosed in this disclosure is capable of modulating the activity of at least one component involved in the regulation of hepcidin expression. In certain embodiments, the anti-TMPRSS6 antibody disclosed in this disclosure is capable of substantially inhibiting TMPRSS6 repression of hepcidin expression. In certain embodiments, the anti-TMPRSS6 antibody disclosed in this disclosure is capable of increasing hepcidin expression. In certain embodiments, the anti-TMPRSS6 antibody disclosed in this disclosure is capable of increasing hepcidin promoter activity. In certain embodiments, the anti-TMPRSS6 antibody disclosed in this disclosure is capable of substantially inhibiting TMPRSS6-induced BMP / SMAD pathway repression of hepcidin expression. The anti-TMPRSS6 antibodies disclosed in the present disclosure may modulate hepcidin expression in a dose-dependent manner, including, but not limited to, substantially inhibiting TMPRSS6 repression of hepcidin expression, increasing hepcidin expression, increasing hepcidin promoter activity, or substantially inhibiting TMPRSS6 repression of BMP / SMAD pathway-induced hepcidin expression. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure can modulate hepcidin expression in a dose-dependent manner. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure can increase serum hepcidin levels in a dose-dependent manner when administered to a subject. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure can decrease serum iron levels in a dose-dependent manner when administered to a subject. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure can increase liver hepcidin RNA levels in a dose-dependent manner when administered to a subject.In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure, when administered to a subject known or suspected to have iron overload, particularly beta-thalassemia, can reduce liver non-heme iron, increase serum hepcidin, increase liver hepcidin RNA, reduce splenomegaly, increase red blood cell count (RBC), reduce hematocrit, reduce red blood cell distribution width (RDW), and increase production of mature red blood cells (increased erythropoiesis).

[0011] In another aspect, the anti-TMPRSS6 antibodies disclosed in the present disclosure exhibit cross-reactivity with at least one non-human TMPRSS6. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure are capable of binding to at least one non-human TMPRSS6 on the surface of a cell expressing at least one non-human TMPRSS6. The anti-TMPRSS6 antibodies disclosed in the present disclosure are capable of binding to human TMPRSS6 and mouse TMPRSS6. The anti-TMPRSS6 antibodies disclosed in the present disclosure are capable of binding to human TMPRSS6 and cynomolgus monkey TMPRSS6. The anti-TMPRSS6 antibodies disclosed in the present disclosure are capable of binding to each of human TMPRSS6, mouse TMPRSS6, and cynomolgus monkey TMPRSS6.

[0012] In another aspect, the anti-TMPRSS6 antibodies disclosed in the present disclosure specifically bind to TMPRSS6 (matriptase-2). In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure bind to TMPRSS6 (matriptase-2) and do not exhibit detectable binding to matriptase homologs. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure bind to human TMPRSS6 (matriptase-2) and do not exhibit detectable binding to human matriptase-1 (ST14). In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure bind to human TMPRSS6 (matriptase-2) and do not exhibit detectable binding to human matriptase-3 (TMPRSS7). In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure bind to human TMPRSS6 (matriptase 2) and do not exhibit detectable binding to either human matriptase-1 (ST14) or human matriptase-3 (TMPRSS7).

[0013] The anti-TMPRSS6 antibodies disclosed in the present disclosure may be monoclonal antibodies, humanized antibodies, chimeric antibodies, single-chain antibodies, Fab fragments, single-chain variable fragments (scFv), recombinant antibodies, aptamers, single-domain antibodies (VHHs, nanobodies), or other TMPRSS6-binding fragments or variants. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure may comprise frameworks in which amino acids have been substituted into existing antibody frameworks to affect properties such as, in particular, antigen-binding ability. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure may comprise a framework from an antibody of a different type (class) and / or organism from the parent antibody, in particular, complementarity-determining regions (CDRs) from a source (parent) antibody grafted (fused) onto an acceptor human framework. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure may include framework regions in which amino acids have been substituted, mutated, or replaced in regions other than the CDRs, such as the variable region framework and / or constant region surrounding the CDRs, particularly the Fc region, to affect properties such as antigen binding or antibody structure. In certain embodiments, one or more CDRs have been substituted, mutated, or replaced. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure may be humanized anti-TMPRSS6 antibody variants.

[0014] In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure comprise at least one polypeptide having an amino acid sequence set forth in Table 1, Table 2, or Table 3, or a sequence substantially identical (e.g., at least 85%, 90%, 92%, 95%, 97%, or 98%, 99% identical) to an amino acid sequence set forth in Table 1, Table 2, or Table 3. The anti-TMPRSS6 antibodies disclosed in the present disclosure may also comprise an amino acid sequence selected from the following, or a sequence substantially identical (e.g., at least 85%, 90%, 92%, 95%, 97%, or 98%, 99% identical) to at least one polypeptide having an amino acid sequence selected from the following: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:41; SEQ ID NO:42; SEQ ID NO:43; SEQ ID NO:44; SEQ ID NO:46; SEQ ID NO:47; SEQ ID NO:48; SEQ ID NO:49; SEQ ID NO:51; SEQ ID NO:52; SEQ ID NO:53; SEQ ID NO:54; SEQ ID NO:56; SEQ ID NO:57; SEQ ID NO:58; SEQ ID NO:59; SEQ ID NO:61; SEQ ID NO:63; SEQ ID NO:65; SEQ ID NO:67; SEQ ID NO:69; SEQ ID NO:71; SEQ ID NO:73; SEQ ID NO:75; SEQ ID NO:77; SEQ ID NO:79; SEQ ID NO:81; or SEQ ID NO:83.

[0015] In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises a heavy chain (HC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 1, or a sequence substantially identical to SEQ ID NO: 1, and a light chain (LC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 6, or a sequence substantially identical to SEQ ID NO: 6. In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises a heavy chain complementarity determining region 1 (HC CDR1) of the amino acid sequence set forth in SEQ ID NO: 2, a heavy chain complementarity determining region 2 (HC CDR2) of the amino acid sequence set forth in SEQ ID NO: 3, a heavy chain complementarity determining region 3 (HC CDR3) of the amino acid sequence set forth in SEQ ID NO: 4, a light chain complementarity determining region 1 (LC CDR1) of the amino acid sequence set forth in SEQ ID NO: 7, a light chain complementarity determining region 2 (LC CDR2) of the amino acid sequence set forth in SEQ ID NO: 8, and a light chain complementarity determining region 3 (LC CDR3) of the amino acid sequence set forth in SEQ ID NO: 9; or a variant of the above antibodies comprising substitutions of 1, 2, 3, 4, 5, or 6 amino acids in the CDR regions. In one non-limiting embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure is the antibody identified in the present disclosure as MWTx-001, which comprises an HC polypeptide having the amino acid sequence set forth in SEQ ID NO: 61 and an LC polypeptide having the amino acid sequence set forth in SEQ ID NO: 63.

[0016] In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises a heavy chain (HC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 11, or a sequence substantially identical to SEQ ID NO: 11, and a light chain (LC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 16, or a sequence substantially identical to SEQ ID NO: 16. In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises an HC CDR1 having the amino acid sequence set forth in SEQ ID NO: 12, an HC CDR2 having the amino acid sequence set forth in SEQ ID NO: 13, an HC CDR3 having the amino acid sequence set forth in SEQ ID NO: 14, an LC CDR1 having the amino acid sequence set forth in SEQ ID NO: 17, an LC CDR2 having the amino acid sequence set forth in SEQ ID NO: 18, and an LC CDR3 having the amino acid sequence set forth in SEQ ID NO: 19, or a variant of the above antibody comprising 1, 2, 3, 4, 5, or 6 amino acid substitutions in the CDR regions. In one non-limiting embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure is the antibody identified in the present disclosure as MWTx-002, which comprises an HC polypeptide having the amino acid sequence set forth in SEQ ID NO: 65 and an LC polypeptide having the amino acid sequence set forth in SEQ ID NO: 67.

[0017] In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises a heavy chain (HC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 21, or a sequence substantially identical to SEQ ID NO: 21, and a light chain (LC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 26, or a sequence substantially identical to SEQ ID NO: 26. In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises an HC CDR1 having the amino acid sequence set forth in SEQ ID NO: 22, an HC CDR2 having the amino acid sequence set forth in SEQ ID NO: 23, an HC CDR3 having the amino acid sequence set forth in SEQ ID NO: 24, an LC CDR1 having the amino acid sequence set forth in SEQ ID NO: 27, an LC CDR2 having the amino acid sequence set forth in SEQ ID NO: 28, and an LC CDR3 having the amino acid sequence set forth in SEQ ID NO: 29, or a variant of the above antibodies comprising substitutions of 1, 2, 3, 4, 5, or 6 amino acids in the CDR regions. In one non-limiting embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure is the antibody identified in the present disclosure as MWTx-003, which comprises an HC polypeptide having the amino acid sequence set forth in SEQ ID NO: 69 and an LC polypeptide having the amino acid sequence set forth in SEQ ID NO: 71.

[0018] In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises a heavy chain (HC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 31, or a sequence substantially identical to SEQ ID NO: 31, and a light chain (LC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 36, or a sequence substantially identical to SEQ ID NO: 36. In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises an HC CDR1 having the amino acid sequence set forth in SEQ ID NO: 32, an HC CDR2 having the amino acid sequence set forth in SEQ ID NO: 33, an HC CDR3 having the amino acid sequence set forth in SEQ ID NO: 34, an LC CDR1 having the amino acid sequence set forth in SEQ ID NO: 37, an LC CDR2 having the amino acid sequence set forth in SEQ ID NO: 38, and an LC CDR3 having the amino acid sequence set forth in SEQ ID NO: 39, or a variant of said antibody comprising 1, 2, 3, 4, 5, or 6 amino acid substitutions in the CDR regions. In one non-limiting embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure is an antibody identified in the present disclosure as humanized anti-TMPRSS6 antibody variant hzMWTx-001Var, which comprises an HC polypeptide having the amino acid sequence set forth in SEQ ID NO: 73 and an LC polypeptide having the amino acid sequence set forth in SEQ ID NO: 75.

[0019] In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises a heavy chain (HC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 41, or a sequence substantially identical to SEQ ID NO: 41, and a light chain (LC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 46, or a sequence substantially identical to SEQ ID NO: 46. In one embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure comprises an HC CDR1 having the amino acid sequence set forth in SEQ ID NO: 42, an HC CDR2 having the amino acid sequence set forth in SEQ ID NO: 43, an HC CDR3 having the amino acid sequence set forth in SEQ ID NO: 44, an LC CDR1 having the amino acid sequence set forth in SEQ ID NO: 47, an LC CDR2 having the amino acid sequence set forth in SEQ ID NO: 48, and an LC CDR3 having the amino acid sequence set forth in SEQ ID NO: 49, or a variant of the above antibodies comprising 1, 2, 3, 4, 5, or 6 amino acid substitutions in the CDR regions. In one non-limiting embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure is an antibody identified in the present disclosure as humanized anti-TMPRSS6 antibody variant hzMWTx-002Var, which comprises an HC polypeptide having the amino acid sequence set forth in SEQ ID NO: 77 and an LC polypeptide having the amino acid sequence set forth in SEQ ID NO: 79.

[0020] In one embodiment, an anti-TMPRSS6 antibody disclosed in the present disclosure comprises a heavy chain (HC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 51, or a sequence substantially identical to SEQ ID NO: 51, and a light chain (LC) variable region polypeptide having the amino acid sequence set forth in SEQ ID NO: 56, or a sequence substantially identical to SEQ ID NO: 56. In one embodiment, an anti-TMPRSS6 antibody disclosed in the present disclosure comprises an HC CDR1 having the amino acid sequence set forth in SEQ ID NO: 52, an HC CDR2 having the amino acid sequence set forth in SEQ ID NO: 53, an HC CDR3 having the amino acid sequence set forth in SEQ ID NO: 54, an LC CDR1 having the amino acid sequence set forth in SEQ ID NO: 57, an LC CDR2 having the amino acid sequence set forth in SEQ ID NO: 58, and an LC CDR3 having the amino acid sequence set forth in SEQ ID NO: 59, or a variant of the above antibodies comprising 1, 2, 3, 4, 5, or 6 amino acid substitutions in the CDR regions. In one non-limiting embodiment, the anti-TMPRSS6 antibody disclosed in the present disclosure is an antibody identified in the present disclosure as humanized anti-TMPRSS6 antibody variant hzMWTx-003Var, which comprises an HC polypeptide having the amino acid sequence set forth in SEQ ID NO: 81 and an LC polypeptide having the amino acid sequence set forth in SEQ ID NO: 83.

[0021] In another aspect, provided are anti-TMPRSS6 antibodies (including variants and fragments as disclosed in this disclosure) that can be used to treat iron overload, particularly disorders of iron metabolism such as β-thalassemia and other disorders of ineffective hematopoiesis. Methods and compositions are provided for using the anti-TMPRSS6 antibodies disclosed in this disclosure for therapeutic uses, including but not limited to, treating iron overload, particularly disorders of iron metabolism such as β-thalassemia and other disorders of ineffective hematopoiesis. In certain embodiments, pharmaceutical compositions are provided that include the anti-TMPRSS6 antibodies disclosed in this disclosure and a suitable carrier and / or excipient.

[0022] In another embodiment, a method for treating an iron metabolism disorder is provided, the method comprising administering an effective amount of an anti-TMPRSS6 antibody disclosed herein to a subject in need thereof, wherein the administration of the effective amount of the anti-TMPRSS6 antibody regulates the activity of a component involved in iron metabolism. In a specific embodiment, a method for treating iron overload comprises administering an effective amount of an anti-TMPRSS6 antibody disclosed herein, wherein the administration of the effective amount of the anti-TMPRSS6 antibody regulates the activity of a component involved in iron metabolism. In a specific embodiment, a method for treating iron overload comprises administering an effective amount of an anti-TMPRSS6 antibody disclosed herein, wherein the administration of the effective amount of the anti-TMPRSS6 antibody regulates the activity of at least one component involved in regulating hepcidin expression. In a specific embodiment, the method comprises administering an effective amount of the anti-TMPRSS6 antibody to inhibit repression of hepcidin expression by TMPRSS6. In a specific embodiment, the administration of an effective amount of the anti-TMPRSS6 antibody increases hepcidin expression. In certain embodiments, the method increases hepcidin promoter activity by administering an effective amount of an anti-TMPRSS6 antibody. In certain embodiments, the method includes inhibiting TMPRSS6-induced repression of hepcidin expression induced by the BMP / SMAD pathway by administering an effective amount of an anti-TMPRSS6 antibody. In certain embodiments, the method includes administering to a subject an effective amount of an anti-TMPRSS6 antibody that produces one or more biological effects associated with iron overload, including, but not limited to, decreased serum iron, decreased liver non-heme iron, increased serum hepcidin, increased liver hepcidin RNA, decreased splenomegaly, increased red blood cell count (RBC), increased hematocrit (HCT), decreased red blood cell distribution width (RDW), and / or increased production of mature red blood cells (increased erythropoiesis).

[0023] In another aspect, there is provided a method for treating a disease or disease state associated with abnormal suppression of hepcidin expression, the method comprising administering to a subject in need thereof an effective amount of an anti-TMPRSS6 antibody disclosed herein, wherein the administration of the effective amount of the anti-TMPRSS6 antibody modulates the activity of at least one component involved in the abnormal suppression of hepcidin expression, thereby alleviating the abnormal suppression of hepcidin expression. In certain embodiments, the method results in increased expression of hepcidin.

[0024] In another embodiment, a method for treating an iron metabolism disorder associated with suppressed hepcidin levels is provided, the method comprising administering an effective amount of an anti-TMPRSS6 antibody disclosed herein to a subject in need thereof, wherein the administration of the effective amount of the anti-TMPRSS6 antibody modulates the activity of a component involved in suppressing hepcidin levels. In certain embodiments, the method comprises administering an effective amount of the anti-TMPRSS6 antibody that increases serum hepcidin levels, increases liver hepcidin RNA, and reduces serum iron levels.

[0025] In another aspect, a method is provided for treating a disorder of iron metabolism, including a disorder associated with and / or characterized by ineffective hematopoiesis, which may include, but is not limited to, β-thalassemia. According to this aspect, the method comprises administering an effective amount of an anti-TMPRSS6 antibody disclosed herein to a subject known or suspected to have a disorder of iron metabolism associated with and / or characterized by ineffective hematopoiesis, wherein the administration results in one or more alterations related to iron metabolism and / or erythropoiesis in the subject. In certain embodiments, a method is provided in which administering an effective amount of an anti-TMPRSS6 antibody treats or ameliorates at least one biological effect or symptom associated with the disorder. In certain embodiments, practicing the method results in one or more alterations, including, but not limited to, decreased liver non-heme iron, increased serum hepcidin, increased liver hepcidin RNA, decreased splenomegaly, increased red blood cell count (RBC), increased hematocrit (HCT), decreased red blood cell distribution width (RDW), and increased production of mature red blood cells (increased erythropoiesis).

[0026] In another aspect, a method for diagnosing or screening for iron overload in a subject is provided. In certain embodiments, the method comprises administering an anti-TMPRSS6 antibody to a subject known or suspected to have iron overload and measuring one or more biological effects or symptoms associated with iron overload.

[0027] In another aspect, one or more isolated nucleic acid molecules are provided that encode at least a portion of at least one of the anti-TMPRSS6 antibodies disclosed in this disclosure. In certain embodiments, the isolated nucleic acid molecule encoding at least a portion of at least one of the anti-TMPRSS6 antibodies disclosed in this disclosure comprises a nucleotide sequence set forth in Table 1, Table 2, or Table 3, or a sequence substantially identical (e.g., at least 85%, 90%, 92%, 95%, 97%, 98%, 99% identical) to a nucleotide sequence set forth in Table 1, Table 2, or Table 3. In certain embodiments, an isolated nucleic acid molecule encoding at least one of the heavy chain (HC) sequences of the anti-TMPRSS6 antibodies disclosed in the present disclosure may comprise a nucleotide sequence selected from at least one of SEQ ID NO:5 or a sequence substantially identical to SEQ ID NO:5, SEQ ID NO:15 or a sequence substantially identical to SEQ ID NO:15, SEQ ID NO:25 or a sequence substantially identical to SEQ ID NO:25, SEQ ID NO:35 or a sequence substantially identical to SEQ ID NO:35, SEQ ID NO:45 or a sequence substantially identical to SEQ ID NO:45, SEQ ID NO:55 or a sequence substantially identical to SEQ ID NO:55, SEQ ID NO:62 or a sequence substantially identical to SEQ ID NO:62, SEQ ID NO:66 or a sequence substantially identical to SEQ ID NO:66, SEQ ID NO:70 or a sequence substantially identical to SEQ ID NO:70, SEQ ID NO:74 or a sequence substantially identical to SEQ ID NO:74, SEQ ID NO:78 or a sequence substantially identical to SEQ ID NO:78, or SEQ ID NO:82 or a sequence substantially identical to SEQ ID NO:82.In certain embodiments, an isolated nucleic acid molecule encoding at least one of the light chain (LC) sequences of an anti-TMPRSS6 antibody or antigen-binding fragment thereof disclosed in the present disclosure may comprise a nucleotide sequence selected from at least one of SEQ ID NO: 10 or a sequence substantially identical to SEQ ID NO: 10, SEQ ID NO: 20 or a sequence substantially identical to SEQ ID NO: 20, SEQ ID NO: 30 or a sequence substantially identical to SEQ ID NO: 30, SEQ ID NO: 40 or a sequence substantially identical to SEQ ID NO: 40, SEQ ID NO: 50 or a sequence substantially identical to SEQ ID NO: 50, SEQ ID NO: 60 or a sequence substantially identical to SEQ ID NO: 60, SEQ ID NO: 64 or a sequence substantially identical to SEQ ID NO: 64, SEQ ID NO: 68 or a sequence substantially identical to SEQ ID NO: 68; SEQ ID NO: 72 or a sequence substantially identical to SEQ ID NO: 72; SEQ ID NO: 76 or a sequence substantially identical to SEQ ID NO: 76; SEQ ID NO: 80 or a sequence substantially identical to SEQ ID NO: 80, or SEQ ID NO: 84 or a sequence substantially identical to SEQ ID NO: 84.

[0028] In another aspect, vectors are provided that comprise one or more nucleic acid molecules encoding at least one amino acid sequence of an anti-TMPRSS6 antibody disclosed in the present disclosure. In certain embodiments, vectors are provided that comprise one or more nucleic acid molecules encoding at least one heavy chain (HC) or light chain (LC) sequence of an anti-TMPRSS6 antibody disclosed in the present disclosure. In certain embodiments, vectors are provided that comprise nucleic acid molecules that encode at least a portion of at least one of the amino acid sequences set forth in Table 1, Table 2, or Table 3, or at least a portion of an amino acid sequence substantially identical to an amino acid sequence set forth in Table 1, Table 2, or Table 3. In certain embodiments, vectors are provided that comprise nucleic acid molecules that encode at least a portion of at least one of the HC or LC sequences set forth in Table 1, Table 2, or Table 3, or at least a portion of an amino acid sequence substantially identical to at least one of the HC or LC sequences set forth in Table 1, Table 2, or Table 3.

[0029] In another aspect, at least one host cell is provided that comprises a vector comprising one or more nucleic acid molecules encoding the amino acid sequence of an anti-TMPRSS6 antibody disclosed in the present disclosure. In certain embodiments, a host cell is provided that contains a vector comprising a nucleic acid molecule encoding at least a portion of at least one of the HC or LC sequences set forth in Table 1, Table 2, or Table 3, or at least a portion of an amino acid sequence substantially identical to at least one of the HC or LC sequences set forth in Table 1, Table 2, or Table 3. In certain embodiments, at least one host cell is capable of supporting expression of the vector and recombinant production of the anti-TMPRSS6 antibody or antigen-binding fragment thereof encoded by the vector. In certain embodiments, at least one host cell is capable of supporting vector expression and recombinant production of the anti-TMPRSS6 antibody or antigen-binding fragment thereof encoded by a vector comprising a nucleic acid molecule encoding at least a portion of at least one of the HC or LC sequences set forth in Table 1, Table 2, or Table 3, or at least a portion of an amino acid sequence substantially identical to at least one of the HC or LC sequences set forth in Table 1, Table 2, or Table 3. In certain embodiments, host cells are transiently transfected with a vector comprising one or more nucleic acid molecules encoding the amino acid sequence of an anti-TMPRSS6 antibody or antigen-binding fragment thereof disclosed in the present disclosure, and the host cells are capable of supporting expression of the vector and recombinant production of the anti-TMPRSS6 antibody or antigen-binding fragment thereof encoded by the vector. [Brief explanation of the drawings]

[0030] [Figure 1] These are the results of cascade screening of anti-TMPRSS6 antibodies. Antibodies that bind to human TMPRSS6 were evaluated using an in vitro functional assay of HAMP promoter activity, and antibodies that showed an effect on HAMP promoter activity were evaluated for cross-reactivity with non-human TMPRSS6. [Figures 2A-2F]Figures 2A-2F show the effects of anti-TMPRSS6 antibodies on HAMP promoter activity measured by a dual-luciferase reporter assay performed in HepG2 cells across a range of antibody concentrations. In each plot, open circles represent results using anti-TMPRSS6 antibodies, and open squares represent results using the same concentrations of mouse IgG or human IgG1 as negative (nonspecific binding) controls. Figure 2A shows the effect of the MWTx-001 anti-TMPRSS6 antibody on HAMP promoter activity across a range of antibody concentrations. Figure 2B shows the effect of the MWTx-002 anti-TMPRSS6 antibody on HAMP promoter activity across a range of antibody concentrations. Figure 2C shows the effect of the MWTx-003 anti-TMPRSS6 antibody on HAMP promoter activity across a range of antibody concentrations. Figure 2D shows the effect of the hzMWTx-001Var anti-TMPRSS6 antibody on HAMP promoter activity across a range of antibody concentrations. Figure 2E and Figure 2F show the effects of the hzMWTx-002Var and hzMWTx-003Var anti-TMPRSS6 antibodies on HAMP promoter activity across a range of antibody concentrations. [Figures 3A-3M]Figures 3A to 3M show the results of measuring the binding affinity of anti-TMPRSS6 antibodies. Figures 3A to 3F show the results of measuring the binding affinity of anti-TMPRSS6 antibodies to human TMPRSS6 expressed on HEK293T cells using two different methods. In each plot, open circles represent the results when a range of anti-TMPRSS6 antibody concentrations was used, and open squares represent the results when the same concentration of mouse IgG was used as a negative control. Figures 3A to 3C show the results of measuring the binding of MWTx-001 (Figure 3A), MWTx-002 (Figure 3B), and MWTx-003 (Figure 3C) to human TMPRSS6 using cell surface ELISA (measurement of HRP-conjugated secondary antibodies). The calculated EC50 value of each antibody was used as an estimate of binding affinity. Figures 3D-3F show the binding of MWTx-001 (Figure 3D), MWTx-002 (Figure 3E), and MWTx-003 (Figure 3F) to human TMPRSS6 measured using FACS (measured with an APC-conjugated secondary antibody). The calculated EC50 value of each antibody was used as an estimate of binding affinity. Figures 3G-3M show the affinity and binding kinetics of anti-TMPRSS6 antibodies to human ecto-TMPRSS6-FLAG measured using Octet® RED96e at analyte concentrations of 50 nM, 25 nM, 12.5 nM, 6.25 nM, 3.13 nM, 1.56 nM, and 0.78 nM. Figure 3G shows the binding kinetics of the MWTx-001 anti-TMPRSS6 antibody to ecto-TMPRSS6-FLAG. Figure 3H shows the binding kinetics of the MWTx-002 anti-TMPRSS6 antibody to ecto-TMPRSS6-FLAG. Figure 3I shows the binding kinetics of the MWTx-003 anti-TMPRSS6 antibody to ecto-TMPRSS6-FLAG. Figure 3J shows the binding kinetics of the hzMWTx-001Var anti-TMPRSS6 antibody to ecto-TMPRSS6-FLAG. Figure 3K shows the binding kinetics of the hzMWTx-002Var anti-TMPRSS6 antibody to ecto-TMPRSS6-FLAG. Figure 3L shows the binding kinetics of the hzMWTx-003Var anti-TMPRSS6 antibody to ecto-TMPRSS6-FLAG. Figure 3M summarizes the affinity measurements of all anti-TMPRSS6 antibodies. [Figure 4A-4U]Figures 4A to 4U show the results of measuring the cross-reactivity of anti-TMPRSS6 antibodies. Figures 4A to 4I show the results of measuring the cross-reactivity of anti-TMPRSS6 antibodies MWTx-001, MWTx-002, and MWTx-003 with human TMPRSS6 and non-human TMPRSS6 expressed on HEK293T cells. Each histogram plot shows the FACS results of incubating HEK293T cells expressing a TMPRSS6 target (thin line, light fill; shown with the antibody name) with a single antibody, and the FACS results of incubating control HEK293T cells not expressing TMPRSS6 protein (thick line, dark fill; shown with Ctrl) with the same antibody. Figures 4A-4C show the results of using HEK293T cells stably expressing human TMPRSS6 (HuTMPRSS6-(His)6) together with MWTx-001 (Figure 4A), MWTx-002 (Figure 4B), and MWTx-003 (Figure 4C). Figures 4D-4F show the results of using HEK293T cells stably expressing mouse TMPRSS6 (MoTMPRSS6-(His)6) together with MWTx-001 (Figure 4D), MWTx-002 (Figure 4E), and MWTx-003 (Figure 4F). Figures 4G to 4I show the results of using HEK293T cells transiently expressing cynomolgus monkey TMPRSS6 (CynoTMPRSS6-(His)6) together with MWTx-001 (Figure 4G), MWTx-002 (Figure 4H), and MWTx-003 (Figure 4I).Figures 4J to 4U show the cross-reactivity of anti-TMPRSS6 antibodies to non-human (mouse (Figures 4J, 4L, 4N, 4P, 4R, 4T) or cynomolgus monkey (Figures 4K, 4M, 4O, 4Q, 4S, 4U)) TMPRSS6 expressed on HEK293T cells using cell surface ELISA (measured with an HRP-conjugated secondary antibody). Figures 4A-4C show the binding of the 2 anti-TMPRSS6 antibody (Figures 4L-4M), the MWTx-003 anti-TMPRSS6 antibody (Figures 4N-4O), the hzMWTx-001Var anti-TMPRSS6 antibody (Figures 4P-4Q), the hzMWTx-002Var anti-TMPRSS6 antibody (Figures 4R-4S), and the hzMWTx-003Var anti-TMPRSS6 antibody (Figures 4T-4U) to non-human TMPRSS6. In each plot, open circles represent results using the anti-TMPRSS6 antibody, and open squares represent results using mouse IgG or human IgG1 as negative (nonspecific binding) controls. The EC50 value of each antibody is used as an estimate of binding affinity. [Figures 5A-5R] Figures 5A to 5R show the results of FACS analysis of the binding of the anti-TMPRSS6 monoclonal antibodies MWTx-001 (Figures 5A to 5C), MWTx-002 (Figures 5D to 5F), and MWTx-003 (Figures 5G to 5I) to HEK293T cells expressing homologous matriptase. HEK293T cells stably expressing human TMPRSS6 (matriptase-2) (Figure 5A, 5D, 5G, 5J, 5M, 5P) were used as a positive control, and HEK293T cells overexpressing matriptase (ST14) (Figure 5B, 5E, 5H, 5K, 5N, 5Q) and / or matriptase-3 (TMPRSS7) (Figure 5C, 5F, 5I, 5L, 5O, 5R) proteins were used to test binding to homologous matriptase. In each panel (Figure 5A-5R), HEK293T cells not expressing matriptase (HEK293T) were used as a negative control to clearly show the results of the control (Ctrl). [Figures 6A-6L]Figures 6A-6L show that anti-TMPRSS6 antibody treatment increased hepcidin expression in mice in a dose-dependent manner. Figures 6A-6C show the effects of the MWTx-003 anti-TMPRSS6 antibody (Figures 6A-6B) or its humanized variant hzMWTx-003Var anti-TMPRSS6 antibody (Figure 6C) on serum iron. Figure 6D shows the effects of GFP-TMPRSS6 on serum hepcidin. Figures 6D-6F show the effects of the MWTx-003 anti-TMPRSS6 antibody (Figures 6D-6E) or its humanized variant hzMWTx-003Var anti-TMPRSS6 antibody (Figure 6F) on serum hepcidin. Figure 6G shows the effects of GFP-TMPRSS6 on liver hepcidin RNA. Figures 6G-6I show the effects of the MWTx-003 anti-TMPRSS6 antibody (Figures 6G-6H) or its humanized variant hzMWTx-003Var anti-TMPRSS6 antibody (Figure 6I) on hepatic hepcidin RNA. Figures 6J-6L show the serum concentrations of the MWTx-003 anti-TMPRSS6 antibody (Figures 6J-6K) or its humanized variant hzMWTx-003Var anti-TMPRSS6 antibody (Figure 6L). Mouse IgG2b (MoIG2b) (Figures 6A-6B, 6D-6E, 6G-6H, 6J-6K) or human IgG1 (HuIGg1) (Figures 6C, 6F, 6I, 6L) were used as isotype controls, PBS was used as a vehicle control, and the GFP vector was used as a vector control (Figures 6A, 6D, 6G, 6J). [Figures 7A-7R]Figures 7A to 7R show the in vivo efficacy of anti-TMPRSS6 antibodies using a β-thalassemia mouse model. Figures 7A to 7D show the effects of the MWTx-003 anti-TMPRSS6 antibody on RBC (Figure 7A), HGB (Figure 7B), HCT (Figure 7C), and RDW (Figure 7D) using Th3 / + mice. Figure 7E shows the effects of the MWTx-003 anti-TMPRSS6 antibody on spleen weight using Th3 / + mice. Figure 7F shows the effects of the MWTx-003 anti-TMPRSS6 antibody on serum iron using Th3 / + mice. Figure 7G shows the effects of the MWTx-003 anti-TMPRSS6 antibody on hepatic non-heme iron using Th3 / + mice. Figure 7H shows the effects of the MWTx-003 anti-TMPRSS6 antibody on serum hepcidin using Th3 / + mice. Figure 7I shows the effect of MWTx-003 anti-TMPRSS6 antibody on liver hepcidin RNA in Th3 / + mice. Figure 7J shows the serum concentration of MWTx-003 anti-TMPRSS6 antibody in Th3 / + mice. Figures 7L-7M show the effect of MWTx-003 anti-TMPRSS6 antibody on erythropoiesis using bone marrow from Th3 / + mice. Figures 7O-7P show the effect of MWTx-003 anti-TMPRSS6 antibody on erythropoiesis using spleen cells from Th3 / + mice. Representative plots in Figures 7K-7P highlight four distinct cell clusters (I: basophilic erythroblasts, II: polychromatic erythroblasts, III: normochromatic erythroblasts and anucleated reticulocytes, IV: mature erythrocytes) and their corresponding percentages of cell numbers. Wild-type mice were used as positive controls (Figures 7A-7J, 7K, and 7N), and mouse IgG2b (MoIgG2b) was used as an isotype control (Figures 7A-7J, 7L, and 7O). The bar graphs in Figures 7Q-7R show the average results for cell clusters I, II, III, and IV in the bone marrow (Figure 7Q) and spleen (Figure 7R) of each treatment regimen (WT, Th3 / +w / MoIgG2b, and Th3 / +w / MWTx-003) after 4 weeks. Comparison of these populations allows for the identification of shifts in each population, particularly toward mature erythrocytes after MWTx-003 treatment. [Figures 8A-8D]Figures 8A to 8D show the results of epitope binning of the MWTx-001, MWTx-002, and MWTx-003 anti-TMPRSS6 antibodies against human ecto-TMPRSS6-FLAG using Octet® RED96e. Figure 8A shows epitope binning of the MWTx-001 anti-TMPRSS6 antibody against ecto-TMPRSS6-FLAG. Figure 8B shows epitope binning of the MWTx-002 anti-TMPRSS6 antibody against ecto-TMPRSS6-FLAG. Figure 8C shows epitope binning of the MWTx-003 anti-TMPRSS6 antibody against ecto-TMPRSS6-FLAG. Figure 8D summarizes the association signals of the MWTx-001, MWTx-002, and MWTx-003 anti-TMPRSS6 antibodies. DETAILED DESCRIPTION OF THE INVENTION

[0031] The present invention relates to novel antibodies and antigen-binding fragments thereof that bind to TMPRSS6, as well as methods for producing and using antibodies that bind to TMPRSS6. Terms / Definitions

[0032] Scientific and technical terms used in connection with the present invention shall have the meanings commonly understood by those of ordinary skill in the art unless otherwise defined. Use of singular terms (such as "a" or "an" or "the" or other singular term use) includes plural references, and plural terms include the singular, unless the context clearly dictates otherwise. Thus, for example, reference to an "antibody" includes "one or more" antibodies or a "plurality" of such antibodies. All publications mentioned in this disclosure are incorporated herein by reference in their entirety.

[0033] In general, the antibodies, antigen-binding fragments, compositions, and methods disclosed in this disclosure may employ the nomenclature and techniques of molecular biology, microbiology, cell and tissue culture, protein and nucleotide chemistry, and recombinant DNA technology available to those of skill in the art. The techniques and procedures described in this disclosure are generally performed according to conventional methods well known in the art and as described in various general and more specific references, particularly Sambrook et al. (1989) MOLECULAR CLONING: A LABORATORY MANUAL (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) and Ausubel et al. (1994) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Volumes I-III (John Wiley & Sons, NY). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or methods commonly accomplished in the art, or as described in this disclosure, unless otherwise indicated in this disclosure. Techniques and methods relating to the preparation and formulation of pharmaceutical agents and the treatment of subjects are described in this disclosure using conventional nomenclature.

[0034] An "antibody" broadly refers to a polypeptide or combination of polypeptides that recognizes and binds to an antigen through one or more immunoglobulin variable regions, whether naturally occurring or non-naturally occurring, for example, as a result of engineering, chimerization, humanization, optimization, CDR-grafting, or affinity maturation.

[0035] The "antibody" disclosed in this disclosure can be a whole (intact, full-length) antibody, a single-chain antibody, or an antigen-binding fragment having one or two chains, and can be naturally or non-naturally occurring. An antibody has at least sufficient complementarity-determining regions (CDRs) interspersed with framework regions (FRs) to recognize and bind to an antigen. The anti-TMPRSS6 antibody disclosed in this disclosure can be, but is not limited to, at least one of a monoclonal antibody, a polyclonal antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, a Fab fragment, a single-chain variable fragment (scFv), an aptamer, a single-domain antibody (VHH or nanobody), a recombinant antibody, an antibody modified by adding a peptide / other moiety to the antibody, and / or an antibody modified by adding amino acids to the N-terminus or C-terminus, or other TMPRSS6-binding fragment or variant. The terms "whole antibody," "full-length antibody," "intact antibody," "naturally occurring antibody," or equivalent terms refer to a polypeptide, particularly a glycoprotein, comprising at least two heavy chains (HC) and two light chains (LC) interconnected by disulfide bonds. Each HC consists of a heavy chain variable region (VH) and an HC constant region (CH), and each light chain consists of a light chain variable region (VL) and an LC constant region (CL). The variable regions of the HC and LC, VH and VL, contain the binding domains that interact with antigens. The VH and VL regions can be further divided into CDR regions, characterized by hypervariability, and FR regions, which are generally highly conserved. Each VH and VL typically consists of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The constant regions of an antibody may mediate the binding of the immunoglobulin to host tissues and factors, including various cells of the immune system and the classical complement system. Typically, an antibody comprises at least heavy chain (HC) CDR1, CDR2, and CDR3 sequences and light chain (LC) CDR1, CDR2, and CDR3 sequences, any one of which may be naturally occurring or non-naturally occurring. An antibody may have fewer CDR sequences as long as it is able to recognize and bind to an antigen.

[0036] The anti-TMPRSS6 antibodies disclosed in the present disclosure may be variants containing at least one altered CDR or framework sequence, and the CDR and / or framework sequence may be optimized by mutating a nucleic acid molecule encoding such a framework sequence. It is also possible to construct variants in which the HC and LC portions are derived independently from different sources. Techniques for creating variants include, but are not limited to, conservative amino acid substitution, computer modeling, screening of candidate polypeptides alone or in combination, and codon optimization, and it will be understood that those skilled in the art can create antibody variants as needed. The anti-TMPRSS6 antibodies disclosed in the present disclosure may be fragments. The antigen-binding function of an antibody can be maintained by a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains, a F(ab) ... )2 Antigen-binding moieties can be incorporated into single-domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and bis-scFvs (see, e.g., Hollinger and Hudson, 2005, Nature Biotechnology, 23, 9, 1126-1136). Antigen-binding moieties of antibodies can be grafted onto polypeptide-based scaffolds to form monobodies (see, e.g., U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide monobodies).

[0037] The term antibody encompasses a wide variety of biochemically distinct polypeptide classes. The "class" of an antibody refers to the type of constant domain or region possessed by its heavy chain. Those skilled in the art will understand that there are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, several of which are further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2, each of which is well characterized and known to confer functional specialization. Modified versions of each of these classes and isotypes are readily identifiable and are within the scope of this disclosure. While all immunoglobulin classes are within the scope of this disclosure, this disclosure will be primarily directed to the IgG class of immunoglobulin molecules.

[0038] A chimeric antibody refers to an antibody in which the portions of the heavy chain (HC) and / or light chain (LC) involved in forming the immune reactive site are derived from a particular source or species, while the remainder of the HC and / or LC are derived from a different source or species. In certain embodiments, the target binding region or site is of non-human origin (e.g., murine or non-human primate) and the constant region is human.

[0039] As used herein, the term "humanized antibody" refers to an antibody or antibody variant derived from a non-human antibody, typically a murine monoclonal antibody, in which CDRs from the parent non-human antibody have been grafted (fused) onto a human immunoglobulin framework, particularly a framework comprising a variable region derived from an acceptor human framework or a human consensus framework. Techniques and principles for designing, producing, and testing humanized antibodies are known (Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing complementarity-determining regions in human antibodies with those from a mouse. Nature. 1986 May 29-Jun 4;321(6069):522-5; Almagro JC, Fransson J. Humanization of Antibodies. Front Biosci. 2008 Jan 1;13:1619-33). It is understood that modifications can be made to the acceptor framework at multiple positions to develop humanized antibodies with improved characteristics depending on the desired application, such as higher affinity for the target, lower clearance, lower toxicity, etc. The anti-TMPRSS6 antibodies disclosed in the present disclosure may be humanized variants.

[0040] "Affinity" refers to the strength of the sum total of non-covalent interactions between one binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, binding affinity as used in this disclosure refers to the intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). Affinity can be measured by common methods known in the art, including those described in this disclosure. The calculated concentration at which approximately 50% of maximal binding occurs (calculated EC 50 ) can be used as an estimate of affinity. The affinity of a molecule X for a partner Y is generally determined by the dissociation constant (Kd or KD, the k off / k on (which represents the

[0041] A "subject" is a mammal, including, but not limited to, primates (e.g., humans and non-human primates such as monkeys), livestock (e.g., cows, sheep, cats, dogs, pigs, llamas, and horses), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the subject is a human. The phrases "to a subject in need thereof" or "to a patient in need thereof" or "to a patient in need of treatment" or "to a subject in need of treatment" can include subjects who would benefit from administration of an anti-TMPRSS6 antibody disclosed in the present disclosure for the treatment of iron overload. It is understood that administration of an anti-TMPRSS6 antibody to a "subject in need thereof" can be interpreted as referring to a subject who is known or suspected to have iron overload, particularly β-thalassemia, based on indicators such as symptoms, family history, and genotype. Additionally, anti-TMPRSS6 antibodies can be administered to subjects not known or suspected to have a disorder of iron metabolism for purposes other than, but not limited to, prophylactic or preventative purposes, screening purposes, diagnostic purposes, research purposes, or to achieve an outcome other than treatment of a disorder.

[0042] An "effective amount" of an anti-TMPRSS6 antibody refers to, for example, an amount in a pharmaceutical formulation effective at a dosage and for a period of time necessary to achieve a desired therapeutic or prophylactic effect. It is understood that "effective amount" is intended to refer to the amount of an anti-TMPRSS6 antibody or pharmaceutical composition containing an anti-TMPRSS6 antibody that elicits a biological response or desired therapeutic effect in a cell, tissue, system, non-human animal subject, non-human mammalian subject, or human subject being measured. The terms "therapeutically effective amount," "pharmacologically effective amount," and "physiologically effective amount" are used interchangeably to refer to the amount of an anti-TMPRSS6 antibody required to provide a threshold level of the active ingredient in the bloodstream or target tissue. The exact amount will depend on many factors, such as the specific anti-TMPRSS6 antibody (active agent), the components and physical characteristics of the composition, the intended population of subjects / patients to be treated, and considerations such as the subject's condition, age, sex, and weight, and can be readily determined by one of ordinary skill in the art based on the information provided in this disclosure or other information available in the relevant literature. The terms "improvement," "increase," or "decrease" as used in this context refer to a value or parameter relative to a baseline measurement, such as a measurement in the same subject prior to the initiation of a treatment described herein, or a measurement in a control individual (or control individuals) in the absence of a treatment described herein.

[0043] The terms "pharmaceutical composition" and "pharmaceutical formulation" refer to a formulation in a form that allows the biological activity of the active ingredient contained therein, particularly an anti-TMPRSS6 antibody, to be effective. It is understood that a pharmaceutical composition may contain two or more active ingredients, for example, two or more anti-TMPRSS6 antibodies, or a combination of an anti-TMPRSS6 antibody with another active ingredient acting on a different target. Such combinations may include, but are not limited to, a combination of an anti-TMPRSS6 antibody with another active ingredient having a desired effect on the hematopoietic process, particularly erythropoiesis, a combination of an anti-TMPRSS6 antibody with a gene therapy agent, such as a gene therapy agent targeting the HBB gene, or a combination of an anti-TMPRSS6 antibody with an Fc fusion protein that targets a TGF superfamily ligand and promotes erythropoiesis. A "pharmaceutically acceptable carrier" refers to any ingredient in a pharmaceutical formulation other than the active ingredient that is non-toxic to a subject. It is understood that a pharmaceutically acceptable carrier may be, but is not limited to, a buffer, excipient, stabilizer, adjuvant, or preservative.

[0044] As used herein, "treatment" or "treating," or similar terms, can refer to an outcome deemed beneficial to a particular subject under a defined set of circumstances. Treating a disorder of iron metabolism non-exclusively refers to any of reducing, ameliorating, slowing, interrupting, preventing, mitigating, halting, or reversing the progression or severity of an existing symptom, disorder, condition, or disease, and can further include preventing or delaying the onset of one or more symptoms of iron overload and / or reducing the severity and frequency of one or more symptoms of iron overload. The terms "treat" or "method of treating," or equivalents, can encompass one or more uses of the anti-TMPRSS6 antibodies disclosed in the present disclosure, including, but not limited to, therapeutic, prophylactic, preventative, diagnostic, imaging, and screening uses.

[0045] As used in this disclosure, the term "vector" refers to a nucleic acid molecule capable of propagating a nucleic acid to which it is linked in a host cell into which the vector is introduced. In this disclosure, vectors capable of directing the expression of nucleic acids to which they are operably linked are referred to as "expression vectors." Anti-TMPRSS6 antibody

[0046] Antibodies and antigen-binding fragments are provided that can bind to cell surface TMPRSS6 and modulate the activity of at least one component involved in iron metabolism, particularly at least one component involved in iron overload associated with abnormally suppressed hepcidin expression. Anti-TMPRSS6 antibodies that can bind to cell surface TMPRSS6 and modulate the activity of at least one component involved in regulating hepcidin expression can be used in methods for treating iron overload associated with abnormally suppressed hepcidin expression. Anti-TMPRSS6 antibodies that can bind to cell surface TMPRSS6 and modulate the suppression of hepcidin expression by TMPRSS6 can be used to therapeutically target TMPRSS6 in methods for treating iron overload associated with abnormally suppressed hepcidin expression.

[0047] Once an antibody or fragment specific to TMPRSS6, particularly human TMPRSS6 expressed on the cell surface, is obtained, its desired biological activity of modulating the activity of at least one component involved in iron metabolism can be tested by several methods known to those skilled in the art.

[0048] It is understood that the terms "modulation" or "modulating," or similar terms, as used in this disclosure, can refer to one or more effects that may occur when an anti-TMPRSS6 antibody disclosed in this disclosure binds to its target. "Modulating" and its equivalents can refer to different actions and effects depending on the component under consideration. That is, "modulation" means neutralizing, reversing, inhibiting, blocking, reducing, antagonizing, or otherwise interfering with the activity of a particular component involved in iron metabolism, while with respect to other components involved in iron metabolism, the term modulation can refer to increasing, enhancing, or having an agonistic effect on those components.

[0049] It is understood that the term "component" can refer not only to the target molecule TMPRSS6 but also to downstream processes or pathways involved in iron metabolism. Thus, a component in the sense of a process or pathway can be, but is not limited to, one or more processes involved in regulating hepcidin expression, TMPRSS6 suppression of hepcidin expression, the process of hepcidin expression, regulating hepcidin concentration, increasing hepcidin concentration, hepcidin promoter activity, or TMPRSS6 suppression of BMP / SMAD pathway-induced hepcidin expression, regulating hepatic non-heme iron concentration, splenomegaly, or one or more hematopoietic processes involved in regulating red blood cell count (RBC), hematocrit (HCT), red blood cell distribution width (RDW), and erythropoiesis, particularly the formation of mature red blood cells.

[0050] The anti-TMPRSS6 antibodies disclosed in the present disclosure can be used to therapeutically target at least one component involved in iron metabolism, particularly at least one component involved in iron overload. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure can be used to therapeutically target at least one component involved in regulating hepcidin expression and modulate the activity of the component to achieve increased hepcidin expression. In certain embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure can be used to modulate the activity of the hepcidin promoter to achieve increased hepcidin expression. It is understood that the anti-TMPRSS6 antibodies disclosed in the present disclosure can be used to therapeutically target TMPRSS6 and thereby modulate downstream activities of other components of hepcidin expression, such as, but not limited to, regulating hepatic non-heme iron concentrations, one or more processes involved in splenic hypertrophy, or one or more hematopoietic processes involved in regulating red blood cell count (RBC), hematocrit (HCT), red blood cell distribution width (RDW), and erythropoiesis, particularly the production of mature red blood cells.

[0051] Therapeutic targeting of at least one component involved in iron metabolism using the anti-TMPRSS6 antibodies disclosed herein allows for precise modulation of the target component. It is understood that the use of the anti-TMPRSS6 antibodies disclosed herein to precisely target TMPRSS6 and its downstream effects on at least one component involved in regulating hepcidin expression can avoid undesirable effects, delivery and / or efficacy difficulties, and regulatory hurdles associated with other approaches to the treatment of iron overload currently in use or under development, such as blood transfusions, which may further worsen iron overload; iron chelation, which has low patient compliance; intrusive phlebotomy or splenectomy, which only manage symptoms; gene therapy targeting the HBB gene, which may have permanent pleiotropic effects in multiple systems; gene therapy and gene editing, which have unknown off-target effects; Fc fusion proteins targeting TGF superfamily ligands to inhibit SMAD signaling, which do not reduce the need for iron chelation therapy to manage iron overload; and other approaches that are difficult to control and deliver, such as hepcidin mimetics, antisense or iRNA agents targeting TMPRSS6. It is understood that the use of anti-TMPRSS6 antibodies for precise therapeutic targeting does not preclude the possibility of using anti-TMPRSS6 antibodies in combination with other active ingredients acting on a different target, with antibodies that bind to a different target, with gene therapy agents and methods that target the HBB gene, or with Fc fusion proteins that target TGF superfamily ligands that stimulate erythropoiesis.

[0052] The anti-TMPRSS6 antibodies disclosed in the present disclosure enable the development of treatments that are tailored to each subject (e.g., dosage, frequency of administration), that are easy to continue and discontinue, and that can be used in combination with other treatments. In certain strategic embodiments, the anti-TMPRSS6 antibodies disclosed in the present disclosure can be combined with other treatments that can address multiple therapeutic targets and / or address shortcomings or undesirable effects of either treatment in the combined therapy. Exemplary Embodiments of Anti-TMPRSS6 Antibodies and Their Uses

[0053] Non-limiting exemplary embodiments of the anti-TMPRSS6 antibodies of the present invention are presented herein and particularly disclosed in the Examples, Tables, and Figures. Antibodies capable of binding to TMPRSS6

[0054] As shown in the Examples, a functional cascade can be used to identify and characterize anti-TMPRSS6 antibodies of the present invention. The first step of the cascade involves screening for antibodies capable of binding to human TMPRSS6 on the surface of TMPRSS6-expressing cells (Example 1, Figure 1), followed by a second step of identifying antibodies capable of binding to human TMPRSS6 on the surface of TMPRSS6-expressing cells and modulating the activity of a component involved in iron metabolism, in this case, testing for their ability to increase hepcidin (HAMP) promoter activity (Example 2). As illustrated by the exemplary embodiment shown in Figure 1, the first step identified 143 antibodies (clones) capable of binding to human TMPRSS6 on the surface of TMPRSS6-expressing cells, and the second step identified 10 antibodies (out of the 143 screened) as "active" antibodies (clones) that were able to increase hepcidin (HAMP) promoter activity.

[0055] In the third stage of the functional cascade (Figure 1), ten "active" antibodies were tested for cross-reactivity with non-human TMPRSS6 targets from sources relevant for further study: mouse TMPRSS6, relevant for preclinical efficacy testing in mouse models; and cynomolgus monkey TMPRSS6, relevant for toxicity (safety) testing. As demonstrated by the exemplary embodiment shown in Figure 1, presented in Example 4, and shown in Figure 4, three (3) clones (out of 10 screened) cross-reacted with at least one non-human TMPRSS6 target and were designated MWTx-001, MWTx-002, and MWTx-003. Each monoclonal antibody was sequenced, and the CDRs on each HC and LC were identified (Kabat numbering). The HC and LC sequences were identified as follows: MWTx-001 (SEQ ID NOs: 61(HC) and 63(LC)), MWTx-002 (SEQ ID NOs: 65(HC) and 67(LC)), and MWTx-0039 (SEQ ID NOs: 69(HC) and 71(LC)). The hybridoma cell line producing the MWTx-001 monoclonal antibody was deposited on May 27, 2020, under the terms of the Budapest Treaty with the American Type Culture Collection (ATCC®), 10801 University Boulevard, Manassas, Virginia, 20110, USA, under ATCC Accession No. PTA-126759. The hybridoma cell line producing the MWTx-002 monoclonal antibody has been deposited under the terms of the Budapest Treaty on May 27, 2020, with the American Type Culture Collection (ATCC®), 10801 University Boulevard, Manassas, Virginia, 20110, USA, under ATCC Accession No. PTA-126760.The hybridoma cell line producing the MWTx-003 monoclonal antibody has been deposited under the terms of the Budapest Treaty on May 27, 2020, with the American Type Culture Collection (ATCC®), 10801 University Boulevard, Manassas, Virginia, 20110, USA, under ATCC Accession No. PTA-126761. Humanized variants

[0056] Humanized antibodies, which comprise CDRs derived from non-human sources grafted onto a human-derived antibody framework, are expected to be non-immunogenic when administered to humans. As demonstrated by the exemplary embodiment disclosed in Example 2, humanized anti-TMPRSS6 antibody variants were successfully generated, tested, optimized, and selected. Multiple HC and LC variant candidates were developed in which the CDR sequences were identical but the variable region framework sequences differed at 90% or more of the framework positions. These variants were tested in different HC / LC combinations to identify combinations with desirable characteristics. After initial design and testing, some parent CDR sequences were modified to avoid potential undesirable events such as, but not limited to, aspartic acid isomerization, and some constant region (Fc) modifications were made to achieve desired functions, such as minimizing antibody-dependent cellular cytotoxicity (ADCC). Variants that showed desired antigen-binding affinities were selected for further evaluation and development, resulting in humanized variants hzMWTx-001Var (SEQ ID NOs: 73 (HC) and 75 (LC)), hzMWTx-002Var (SEQ ID NOs: 77 (HC) and 79 (LC)), and hzMWTx-003Var (SEQ ID NOs: 81 (HC) and 83 (LC)). Anti-TMPRSS6 antibody increases hepcidin promoter activity

[0057] As disclosed herein, antibodies for use in treating iron overload disorders characterized by decreased hepcidin expression can modulate the activity of at least one component involved in hepcidin expression, which can be the activity of the hepcidin promoter. As demonstrated by exemplary embodiments using the in vitro assay disclosed in Example 2, the anti-TMPRSS6 antibodies MWTx-001, MWTx-002, MWTx-003, hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var increased HAMP promoter activity in a dose-dependent manner (FIGS. 2A-2F), while the isotype control at the same concentration did not increase HAMP promoter activity. Anti-TMPRSS6 antibodies with high affinity for their targets in relevant biological contexts

[0058] The anti-TMPRSS6 antibodies exhibited high affinity for a biologically relevant target, i.e., human TMPRSS6 expressed on the cell surface. As shown by exemplary embodiments of affinity measurements using three different methods disclosed in Example 3 and Figure 3M, monoclonal antibodies MWTx-001, MWTx-002, and MWTx-003, as well as humanized variants hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var, consistently exhibited favorable affinity properties for a therapeutically effective antibody or antibody fragment. Anti-TMPRSS6 antibodies with cross-reactivity with non-human targets

[0059] A therapeutically useful antibody or antibody fragment desirably has sufficient cross-reactivity with a non-human target (non-human cognate) from a source that will be relevant for further studies, such as preclinical efficacy studies, disease animal models, toxicity studies, etc., so that the antibody or antibody fragment recognizes, for example, a mouse homolog and / or a primate homolog, such as from cynomolgus monkeys. As demonstrated by the exemplary embodiment disclosed in Example 4, MWTx-001, hzMWTx-001Var, MWTx-003, and hzMWTx-003Var showed detectable cross-reactivity with mouse TMPRSS6, while MWTx-001, MWTx-002, MWTx-003, hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var showed detectable cross-reactivity with cynomolgus monkey TMPRSS6. Anti-TMPRSS6 antibody specifically binds to TMPRSS6 (matriptase-2)

[0060] Antibodies with high specific binding to a target protein and low cross-reactivity with homologous proteins within the same organism are expected to have few or no off-target effects. The anti-TMPRSS6 antibodies provided herein exhibit high specificity for human TMPRSS6 (matriptase-2), making them suitable for use in targeting compositions and methods. As demonstrated by the exemplary embodiments disclosed in Example 5 and shown in Figures 5A-R, monoclonal antibodies MWTx-001, MWTx-002, and MWTx-003, as well as their humanized variants hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var, specifically bound to human TMPRSS6 (matriptase-2) without cross-reactivity with the cognate human matriptase. That is, these antibodies did not exhibit detectable binding to matriptase-1 (ST14) or matriptase-3 (TMPRSS7). Anti-TMPRSS6 antibodies have in vivo dose-dependent effects on hormones and symptoms associated with iron overload

[0061] Antibodies capable of increasing serum hepcidin levels, a hormone that regulates iron absorption and mobilization from iron stores, are expected to reduce, ameliorate, or prevent symptoms of iron overload, particularly those associated with elevated serum iron levels. As demonstrated by the exemplary embodiment shown in Example 6, administration of the anti-TMPRSS6 monoclonal antibody MWTx-003 or its humanized variant hzMWTx-003Var to wild-type subjects, i.e., subjects not known or suspected to have iron overload, resulted in increased serum hepcidin levels (Figures 6A-6C), decreased serum iron levels (Figures 6D-6F), and increased liver hepcidin RNA levels (Figures 6G-6I) compared with isotype controls. These effects were dose-dependent, which can be interpreted as indicating that the dose-dependent in vivo effects of anti-TMPRSS6 antibodies allow those skilled in the art to determine effective doses (dosages) for a given subject, regardless of the mechanism of action. Anti-TMPRSS6 antibody is effective in vivo in a β-thalassemia disease model

[0062] Antibodies and antibody fragments that can alleviate iron overload symptoms in vivo when administered to subjects representing animal models of iron overload, i.e., subjects known or suspected to have iron overload, are expected to be therapeutically effective in clinical settings. As demonstrated by an exemplary embodiment shown in Example 7 using a Th3 / + mouse model of β-thalassemia, administration of the anti-TMPRSS6 monoclonal antibody MWTx-003 resulted in multiple effects, including decreased hepatic non-heme iron, increased serum hepcidin, increased liver hepcidin RNA, suppressed splenomegaly, increased red blood cell count (RBC), increased hematocrit (HCT), decreased red blood cell distribution width (RDW), and increased production of mature red blood cells (increased erythropoiesis), compared with an isotype control. Each of these effects can be interpreted as an improvement in the symptoms of the disorder. Symptoms of the disease are manifested in multiple biological systems, including but not limited to, the liver (effects on hepatic non-heme iron, hepatic hepcidin RNA), blood (effects on serum iron concentration, circulating hormone concentrations, particularly serum hepcidin concentration, RBC, HCT, and RDW), spleen size and function (splenomegaly), and erythropoiesis at multiple sites, including but not limited to, the bone marrow and spleen (effects on the abundance of different progenitor cell types and the abundance of mature red blood cells at the site of erythropoiesis). Administration of anti-TMPRSS6 antibodies improved multiple symptoms in disease model subjects, shifting the measured symptom levels from those seen in disease model isotype controls (untreated disease) to those seen in wild-type littermates, representing normal levels in genetically similar subjects not known or suspected to have the disease. Without being bound by theory or mechanism of action, it is understood that ineffective erythropoiesis is driven by abnormal suppression of hepcidin, which leads to increased iron absorption and iron overload, and that treatments that improve erythroblast differentiation and maturation into red blood cells are therapeutically beneficial for treating iron overload. The present non-limiting exemplary embodiments disclose anti-TMPRSS6 antibody therapies that increase erythroblast differentiation and maturation into red blood cells, further reducing iron load. composition

[0063] Compositions are provided that include a safe and effective amount of the anti-TMPRSS6 antibody of the present invention and a pharmaceutically acceptable carrier or excipient(s) suitable for the intended use of each composition. Such carriers include, but are not limited to, saline, buffer, glucose, water, glycerol, ethanol, excipients, stabilizers, preservatives, or combinations thereof. It is understood that pharmaceutical formulations should be tailored to the dosage form.

[0064] The anti-TMPRSS6 antibodies disclosed in the present disclosure can be administered by any suitable means, including, but not limited to, injection or parenteral infusion. Parenteral infusion can include intramuscular, intravenous, intraarterial, intraperitoneal, subcutaneous, or hepatic parenteral administration. The anti-TMPRSS6 antibodies disclosed in the present disclosure can be formulated for introduction into the liver tissue or vasculature for localized delivery to the target tissue. The anti-TMPRSS6 antibodies disclosed in the present disclosure can be administered using a device, as a depot, or in a sustained-release formulation (e.g., a semipermeable matrix of a solid hydrophobic polymer containing the antibody, or a microcapsule), allowing for slow, measured, and / or localized delivery. The anti-TMPRSS6 antibodies disclosed in the present disclosure can be formulated and administered using colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions. method

[0065] Methods for treating disorders of iron metabolism using an effective amount of the anti-TMPRSS6 antibody disclosed in the present disclosure are provided. Without wishing to be bound by a particular mechanism of action, methods provided for targeting TMPRSS6 using the anti-TMPRSS6 antibody disclosed in the present disclosure result in multiple downstream effects, particularly effects on components (molecules, systems, processes) involved in iron metabolism and erythropoiesis. Without wishing to be bound by a particular mechanism of action, methods for treating disorders of iron metabolism using an effective amount of the anti-TMPRSS6 antibody disclosed in the present disclosure to regulate the activity of components involved in iron metabolism are provided. In particular, methods are provided for treating iron overload disorders associated with excessive iron accumulation in tissues and organs, including β-thalassemia, particularly disorders associated with or characterized by ineffective hematopoiesis, which may include, but are not limited to, non-transfusion-dependent thalassemia, MDS (myelodysplastic syndrome), erythroblastic anemia, and sideroblastic anemia. Without being limited to a single mechanism of action, a method for treating iron overload associated with low hepcidin levels, particularly diseases associated with suppressed hepcidin expression (including diseases or conditions associated with abnormal suppression of hepcidin expression) is provided by administering an anti-TMPRSS6 antibody that can increase hepcidin expression.

[0066] The present disclosure provides a method for treating an iron metabolism disorder, comprising administering an effective amount of an anti-TMPRSS6 antibody disclosed in the present disclosure to a subject in need thereof, wherein administration of the effective amount of the anti-TMPRSS6 antibody ameliorates at least one biological effect (symptom) associated with iron metabolism. A method for treating an iron metabolism disorder associated with depressed hepcidin levels is provided, wherein administration of an effective amount of the anti-TMPRSS6 antibody disclosed in the present disclosure to a subject in need thereof results in at least one of increased hepcidin promoter activity, increased hepcidin transcription, increased hepcidin RNA levels, and increased hepcidin levels (particularly serum hepcidin levels). Methods are provided for treating a subject known or suspected of having iron overload, wherein administering an effective amount of an anti-TMPRSS6 antibody results in one or more biological effects, including, but not limited to, a decrease in liver non-heme iron, an increase in serum hepcidin, an increase in liver hepcidin RNA, a decrease in splenomegaly, an increase in red blood cell count (RBC), an increase in hematocrit (HCT), a decrease in red blood cell distribution width (RDW), and an increase in the production of mature red blood cells (increased erythropoiesis). Methods are provided for treating a subject known or suspected of having iron overload, characterized by ineffective hematopoiesis, wherein administering an effective amount of an anti-TMPRSS6 antibody results in one or more biological effects, including, but not limited to, a decrease in liver non-heme iron, an increase in serum hepcidin, an increase in liver hepcidin RNA, a decrease in splenomegaly, an increase in red blood cell count (RBC), an increase in hematocrit (HCT), a decrease in red blood cell distribution width (RDW), and an increase in the production of mature red blood cells (increased erythropoiesis).

[0067] Methods and compositions are provided for treating disorders of iron metabolism, particularly iron overload disorders, and more particularly iron overload disorders characterized by ineffective hematopoiesis, where administration of an effective amount of an anti-TMPRSS6 antibody results in treatment or amelioration of one or more biological effects or symptoms associated with the disorder. Without being bound by theory or mechanism of action, it is understood that ineffective hematopoiesis, characterized by low production of mature red blood cells in the bone marrow due to apoptosis of erythroid precursors, is the driving force behind increased iron absorption and abnormal suppression of hepcidin, which leads to iron overload. Based on this understanding, treatments that improve erythroblast differentiation and maturation into red blood cells are believed to be beneficial for treating iron overload. The effectiveness of anti-TMPRSS6 antibody therapy in increasing erythroblast differentiation and maturation into red blood cells, reducing iron load, increasing hepcidin expression, etc., maximizes the therapeutic benefits of methods and compositions using the anti-TMPRSS6 antibodies disclosed herein.

[0068] The following examples are offered to illustrate, but not to limit, the claimed invention. [Example]

[0069] Example 1: Antibody generation and identification of antibodies that bind to TMPRSS6 The generation of a novel monoclonal antibody against TMPRSS6 was undertaken by LakePharma Discovery Immunology Group (LakePharma, Inc., San Carlos, CA) using in vivo rodent immunization and hybridoma technology. DNA-based immunization was performed in B6;SJL mice (The Jackson Laboratories) using a mixture of pLEV113_huTMPRSS6 and pLEV113_moTMPRSS6-TCE plasmid DNA (cloned at LakePharma, Inc.) via hydrodynamic tail vein injection. Sufficient plasma titers were obtained by fluorescence-activated cell sorting (FACS) to initiate downstream antibody recovery and screening activities. Electrofusion was performed using pooled splenocytes from two immunized mice and their myeloma fusion partners using a NEPA GENE ECFG21 Super Electro Cell Fusion Generator (NEPA Gene Co., Ltd., Ichikawa, Chiba Prefecture, Japan). The fusion material was plated into ten 384-well plates in hypoxanthine-aminopterin-thymidine medium, which specifically selects hybridomas over unfused myeloma partner cells. Hybridoma supernatants were initially screened for HuTMPRSS6 reactivity by FACS analysis. 10 days after fusion, supernatants that gave positive staining signals on TMPRSS6-expressing HEK293T cells (HEK293T cells were transfected with a plasmid encoding huTMPRSS6-(His)6 (SEQ ID NO: 97) and selected for TMPRSS6-expressing HEK293T cells) and negative staining signals on the parent cells (HEK293T) were identified. Hybridoma supernatants that gave positive staining signals on TMPRSS6-expressing HEK293 cells and negative staining signals on the parent cells were designated "hits" and further screened. 192 hits were identified in the primary FACS screen, and 143 hits were identified in the secondary and tertiary FACS screens.

[0070] Example 2: Functional screening of anti-TMPRSS6 antibodies, identification, production, and sequencing of monoclonal anti-TMPRSS6 antibodies and humanized variants. HAMP-luciferase reporter assay

[0071] A hepcidin promoter-luciferase reporter assay was used to measure the response of the HAMP promoter to various anti-TMPRSS6 antibodies (Du, X. et al., 2008, Science 320:1088-1092; modified to use the human HAMP promoter instead of the mouse HAMP promoter as originally described). For the HAMP-luciferase reporter assay, a 2.5 kb HAMP promoter fragment (Reference Genome GRCh38) was spliced ​​upstream of the sequence encoding firefly luciferase. A control construct encoding Renilla luciferase driven by the thymidine kinase promoter (Promega, E6931) was used as an internal control. These constructs were cotransfected with a construct encoding TMPRSS6 into HepG2 cells (ATCC, HB-8065). Transfected HepG2 cells expressing TMPRSS6 were pretreated for approximately 3 hours with various concentrations of purified mAb diluted in starvation medium containing Minimum Essential Medium (MEM, ATCC) + 1% heat-inactivated fetal bovine serum (FBS, Gibco) + 1 mM sodium pyruvate + non-essential amino acid solution (Gibco) + 10 mM HEPES (Gibco) + 1% Pen / Strep (Gibco). They were then treated with recombinant hBMP6 (R&D Systems) at final concentrations of 25–60 ng / ml to induce BMP-SMAD-mediated signaling. Purified mouse IgG (Sigma-Aldrich) or human IgG1 (BioXcell) was used as a control. After overnight hBMP6 treatment, cells were lysed and luciferase substrate was added. Luminescence measurements for firefly luciferase and Renilla luciferase were recorded by measuring total luminescence, respectively. Activity was calculated as the ratio of firefly luciferase luminescence to Renilla luciferase luminescence (control). The results of these assays are shown in Figures 2A-2F. In vitro functional screening

[0072] To screen for functionally active hybridomas, all 143 HuTMPRSS6-binding hybridomas ("hits") were tested using the HAMP-luciferase reporter assay described above. Supernatants from 10 of the 143 HuTMPRSS6-binding hybridomas increased HAMP promoter activity (data not shown) and were identified as "active clones" for further testing. These 10 active clones were tested for cross-reactivity to the murine target MoTMPRSS6, as described in Example 4 below; three showed binding to both HuTMPRSS6 and MoTMPRSS6, as measured by FACS. These three cross-reactive clones were further plated at a density of 1 cell / well in 192 wells of a 384-well plate to generate monoclonal hybridoma clones, and the resulting subclones that showed desirable functional activity and cross-reactivity against non-human targets, such as mouse TMPRSS6 (moTMPRSS6) and cynomolgus monkey TMPRSS6 (cynoTMPRSS6), were identified as MWTx-001, MWTx-002, and MWTx-003. Sequences of anti-TMPRSS6 antibodies MWTx-001, MWTx-002, and MWTx-003

[0073] The sequences of MWTx-001, MWTx-002, and MWTx-003 were determined by isolating mRNA from each hybridoma sample, amplifying the target variable region by reverse transcription-polymerase chain reaction (RT-PCR) using a unique mouse IgG-specific primer set, and sequencing. Unique heavy and light chains were identified for each anti-TMPRSS6 antibody. The nucleotide sequences of each heavy and light chain were determined. The amino acid sequences encoded by the nucleotide sequences were determined, and the CDR regions were identified using the Kabat numbering system. Table 1 shows the amino acid sequences of the heavy and light chain variable regions, as well as the amino acid sequences of the identified CDRs (based on the Kabat numbering system) and the nucleotide sequences of the heavy and light chain variable regions for MWTx-001, MWTx-002, and MWTx-003, respectively. JPEG0007813234000001.jpg227156JPEG0007813234000002.jpg227149JPEG0007813234000003.jpg18149Generation and screening of humanized anti-TMPRSS6 antibody variants

[0074] Humanization of the parent antibody was performed by CDR grafting onto a human antibody framework. First, homology modeling of the parent antibody's three-dimensional structure was performed to establish a structural model of the parent antibody. The amino acid sequences of the variable fragment framework were identified based on overall sequence identity, conformity to the VH-VL interface, the canonical positions of similarly categorized CDRs, and removal of potential N-glycosylation sites. Humanized antibodies were designed by creating multiple hybrid sequences by fusing selected portions of the parent antibody sequence with human framework sequences. The isotypes selected for formatting the humanized antibody were IgG1 for the heavy chain and IgG1 kappa for the light chain. Using the 3D model, these humanized sequences were methodologically analyzed by visual inspection and computer modeling to isolate sequences with a high probability of retaining antigen binding. The goal for the final humanized antibody was to maximize the amount of human sequence while maintaining the specificity of the original antibody. Humanized variants, consisting of humanized VH and VL pairs, were then expressed and purified for affinity analysis.

[0075] In one round of designing, generating, and testing variants as part of affinity analysis, the VH-CDRs of the parent antibody MWTX-003 were placed in corresponding positions on four different human IgG1-derived frameworks to create four VH variants (SEQ ID NOS: 89-92), and the VL-CDRs of the parent antibody MWTX-003 were placed in corresponding positions on four different human IgG1 kappa-derived frameworks to create four VL (VK) variants (SEQ ID NOS: 93-96). A total of 16 humanized variants, representing every combination of VH and VL (VK) variants, were prepared according to a 4VHx4VK matrix and evaluated for antigen-binding properties (k). on , k off , KD) was evaluated and found to be in the nanomolar range, with a KD value of 4.16E-07 (~1.09E-08).

[0076] Variants exhibiting desirable antigen-binding affinities were selected for further evaluation and development, in some cases altering the parental CDR sequences to avoid potential undesirable events such as aspartate isomerization.

[0077] To suppress antibody effector functions, especially antibody-dependent cellular cytotoxicity (ADCC), critical amino acid residues in the Fc region were identified and mutated (substituted) for all humanized antibody variants. Publications on Fc mutations aimed at abolishing ADCC provide guidance, e.g., the native Fc region of hIgG1, as described in (Tamm A, Schmidt RE. IgG binding sites on human Fc gamma receptors. Int Rev Immunol. 1997;16(1-2):57-85. doi:10.3109 / 08830189709045703; Jefferis R, Lund J. Interaction sites on human IgG-Fc for Fc gamma receptors: current models. Immunol Lett. 2002 Jun 3;82(1-2):57-65. doi:10.1016 / s0165-2478(02)00019-6). These have been used to inform mutations such as the removal of an N-linked glycosylation site (N297A mutation) or the substitution of leucines at positions 234 and 235 in the lower hinge region of the Fc (LALA double mutation). In this modification, the N297A mutation was introduced into the Fc of the hzMWTx-001Var and hzMWTx-002Var antibodies, and the LALA mutation was introduced into the Fc of the hzMWTx-003Var antibody, achieving the same goal of reduced or suppressed ADCC (Table 3, SEQ ID NOs: 73, 77, 81).

[0078] After evaluation, humanized anti-TMPRSS6 antibody variants hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var were selected for further testing. The sequences and characteristics of the humanized variants are shown in Tables 2 and 3 below. Recombinant generation of humanized anti-TMPRSS6 antibody variants

[0079] Expression constructs for humanized anti-TMPRSS6 antibody variants were designed with an internal ribosome entry site (IRES) between the LC-encoding and HC-encoding DNA sequences. The constructs were codon-optimized using Geneart DNA synthesis and cloned into the pcDNA3.4 mammalian expression vector (ThermoFisher). The inserted DNA sequences were confirmed by sequencing. For recombinant antibody production, the expression constructs were used for transient transfection using the ExpiCHO expression system (ThermoFisher) according to the manufacturer's instructions. The expressed antibodies were purified by protein A affinity chromatography. The antibody yields from transient transfections ranged from 50 mg to 300 mg per liter, with purity of 95% or greater and endotoxin levels of less than 1 EU / ml. Sequences of humanized anti-TMPRSS6 antibody variants hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var

[0080] The humanized anti-TMPRSS6 antibody variants hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var were selected for further testing. The sequences of each variable region are shown in Table 2 below, where the identified CDRs are underlined and the changes made to the humanized variant CDR sequences compared to the parent antibody are indicated and discussed. JPEG0007813234000004.jpg227157JPEG0007813234000005.jpg227148JPEG0007813234000006.jpg147148

[0081] Table 3 shows the complete heavy and light chain protein and nucleotide sequences of anti-TMPRSS6 monoclonal antibodies MWTx-001, MWTx-002, and MWTx-003, and the humanized anti-TMPRSS6 antibody variants hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var. The heavy chain protein sequences of the humanized anti-TMPRSS6 antibody variants hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var indicate the positions of mutations (changes) introduced to reduce ADCC, as described above. JPEG0007813234000007.jpg227155JPEG0007813234000008.jpg227149JPEG0007813234000009.jpg227152JPEG0007813234000010.jpg227150JPEG0007813234000011.jpg227148JPEG0007813234000012.jpg186148Dose-dependent effect of anti-TMPRSS6 antibody on HAMP promoter activity

[0082] Figures 2A-2F show the results of using the HAMP luciferase reporter assay described above to test MWTx-001, MWTx-002, MWTx-003, and their humanized variants hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var at the indicated concentrations. MWTx-001 (Figure 2A), MWTx-002 (Figure 2B), MWTx-003 (Figure 2C), and the humanized variants hzMWTx-001Var (Figure 2D), hzMWTx-002Var (Figure 2E), and hzMWTx-003Var (Figure 2F) increased HAMP promoter activity in a dose-dependent manner. The EC of MWTx-001 50 The EC value of MWTx-002 was calculated to be 3 μg / ml (Figure 2A). 50 The EC value of MWTx-003 was calculated to be 1 μg / ml (Figure 2B). 50 The EC value of hzMWTx-001Var was calculated to be 2 μg / ml (Figure 2C). 50 The EC value of hzMWTx-002Var was calculated to be 0.8 μg / ml (Figure 2D).50 The EC value of hzMWTx-003Var was calculated to be 0.3 μg / ml (Figure 2E). 50 was calculated to be 0.3 μg / ml (Fig. 2F).

[0083] Example 3: Binding affinity of anti-TMPRSS6 antibodies The binding affinity of various anti-TMPRSS6 antibodies to human TMPRSS6 expressed on HEK293T cells was measured using three different methods: cell surface ELISA (Figures 3A-3C), FACS (Figures 3D-3F), and biolayer interferometry (Figures 3G-3M). Binding affinity measurement of anti-TMPRSS6 mAb using cell surface ELISA

[0084] HEK293T cells stably expressing human TMPRSS6 (produced by LakePharma Inc. as described above; SEQ ID NO: 97) were fixed with 4% paraformaldehyde (PFA), washed with dPBS (Dulbecco's phosphate-buffered saline, Corning Cellgro), and then incubated with various concentrations of anti-TMPRSS6 antibody diluted in BSA medium (DMEM + 1% Pen / Strep + 10 mM HEPES + 1 mg / ml BSA (Sigma-Aldrich)). Purified mouse IgG was used as a control (Sigma-Aldrich). After incubation, cells were washed with BSA medium and subsequently incubated with HRP-conjugated goat anti-mouse IgG (Invitrogen) as the 2° antibody. Finally, cells were washed with dPBS to remove unbound antibody and developed with ELISA liquid substrate (Sigma-Aldrich). The reaction was then stopped by adding an equal volume of 1 M H2SO4 ELISA liquid substrate. Bound antibody was measured at OD 450nm The results of these assays are shown in Figures 3A-3C. Binding affinity measurement of anti-TMPRSS6 mAb using FACS

[0085] HEK293T cells stably expressing human TMPRSS6 were harvested and blocked with dPBS + 3% BSA before incubation with various concentrations of anti-TMPRSS6 antibody diluted in dPBS + 3% BSA. Purified mouse IgG was used as a control. After incubation, cells were washed with dPBS and subsequently incubated with APC-conjugated goat anti-mouse IgG as a 2° antibody (Jackson ImmunoResearch Inc.). Finally, cells were washed with dPBS to remove unbound antibody, resuspended in dPBS + 1 mM EDTA, and then subjected to FACS analysis using a NOVOCYTE® Flow Cytometer (ACEA Biosciences, Inc., San Diego, CA). Bound antibody was determined by measuring the mean APC intensity after excitation at 640 nm and emission (fluorescence) at 675 nm. The results of these assays are shown in Figures 3D–3F. Measurement of the affinity and binding kinetics of anti-TMPRSS6 antibodies using Bio-Layer Interferometry

[0086] Bio-Layer Interferometry was used to measure the affinity and binding kinetics of anti-TMPRSS6 antibodies using the Octet® RED96e system (Sartorius AG). Pre-hydrated anti-mouse IgG Fc capture (AMC) biosensors (for MWTx-001, MWTx-002, and MWTx-003 anti-TMPRSS6 antibodies, Figures 3G-3I) or anti-human IgG Fc capture (AHC) biosensors (for hzMWTx-001Var, hzMWTx-002Var, and hzMWTx-003Var anti-TMPRSS6 antibodies, Figures 3J-3L) were first soaked in 1x KB (kinetic buffer, 1x PBS). After equilibration for 120 seconds in pH 7.4 + 0.02% Tween-20 + 0.1% BSA to establish an initial baseline, 10 mg / ml anti-TMPRSS6 antibodies (MWTx-001, Figure 3G; MWTx-002, Figure 3H; MWTx-003, Figure 3I; hzMWTx-001Var, Figure 3J; hzMWTx-002Var, Figure 3K; hzMWTx-003Var, Figure 3L) were loaded onto the AMC or AHC biosensor for 240 seconds. After establishing a second baseline signal for 120 seconds, various concentrations of human ecto-TMPRSS6-FLAG (SEQ ID NO: 102) (produced in-house by fusing the extracellular domain of human TMPRSS6 with a FLAG tag at the C-terminus) were added for 240 seconds. Finally, the analytes were lysed in 1xKB for 360 seconds. Data analysis was performed using Octet Data Analysis HT Software. on , k off and R 2 are summarized in Figure 3M.

[0087] Example 4: Cross-reactivity: Binding of anti-TMPRSS6 antibodies to human TMPRSS6 and non-human TMPRSS6 Cross-reactivity determination by FACS

[0088] We tested whether the selected anti-TMPRSS6 antibodies could bind to TMPRSS6 derived from mouse and / or cynomolgus monkeys. HEK293T cells stably expressing human TMPRSS6 (HuTMPRSS6-(His)6) (generated by LakePharma Inc. as described above) and mouse TMPRSS6 (MoTMPRSS6-(His)6) were used. )6 HEK293T cells stably expressing TMPRSS6 (SEQ ID NO: 98) (produced by LakePharma Inc. as described above), and cynomolgus monkey TMPRSS6 (CynoTMPRSS6-(His )6 HEK293T cells transiently expressing TMPRSS6 (SEQ ID NO: 99) (in-house produced) were harvested. HEK293T cells stably expressing human TMPRSS6 were used as a positive control, and HEK293T cells were used as a negative control (described above). Cells were blocked with dPBS + 3% BSA and then incubated with anti-TMPRSS6 antibody diluted in dPBS + 3% BSA. After incubation, cells were washed with dPBS and then incubated again with AlexaFluor-488-conjugated goat anti-mouse IgG as a 2° antibody (Invitrogen). Finally, cells were washed with dPBS to remove unbound antibody and resuspended in dPBS + 1 mM EDTA before FACS analysis using a NOVOCYTE® Flow Cytometer (ACEA Biosciences, Inc., San Diego, CA). Bound antibody was determined by exciting at 488 nm and measuring emission (FITC-A) at 530 nm. The results of these assays are shown in the histogram plots in Figures 4A–4I. Cross-reactivity with mouse TMPRSS6 was observed for MWTx-001 (Figure 4D) and MWTx-003 (Figure 4F), whereas MWTx-002 (Figure 4E) showed no detectable cross-reactivity with mouse TMPRSS6. Cross-reactivity with cynomolgus monkey TMPRSS6 was observed for MWTx-001 (Figure 4G), MWTx-002 (Figure 4H), and MWTx-003 (Figure 4I). Cross-reactivity determination by cell surface ELISA

[0089] HEK293T cells stably expressing mouse TMPRSS6 (produced by LakePharma Inc. as described above; Figures 4J, 4L, 4N, 4P, 4R, and 4T) or cynomolgus monkey (produced in-house as described above; Figures 4K, 4M, 4O, 4Q, 4S, and 4U) were fixed with methanol (100%), washed with dPBS (Dulbecco's Phosphate-Buffered Saline, Corning Cellgro) and then incubated with various concentrations of anti-TMPRSS6 antibodies and their humanized variants diluted in BSA medium (DMEM + 1% Pen / Strep + 10 mM HEPES + 1 mg / ml BSA (Sigma-Aldrich)). Purified mouse IgG (Figures 4J–4O) or human IgG1 (Figures 4P–4U) were used as controls. After incubation, cells were washed with BSA medium and then incubated with HRP-conjugated goat anti-mouse (Invitrogen, Figures 4J-4O) or anti-human (Millipore, Figures 4P-4U) IgG as the 2° antibody. Finally, cells were washed with dPBS to remove unbound antibodies and developed with ELISA liquid substrate (Sigma-Aldrich). The reaction was then stopped by adding an equal volume of 1M H2SO4 ELISA liquid substrate. Bound antibodies were detected at OD 450nm The absorbance of the antibody was measured at 1000 kJ / min. The results of these assays are shown in Figures 4J–4U. Cross-reactivity with mouse TMPRSS6 was observed with the MWTx-001 (Figure 4J) and MWTx-003 (Figure 4N) anti-TMPRSS6 antibodies and their humanized variants, hzMWTx-001Var (Figure 4P) and hzMWTx-003Var (Figure 4T). However, no detectable cross-reactivity with mouse TMPRSS6 was observed with the MWTx-002 (Figure 4L) anti-TMPRSS6 antibody or its humanized variant, hzMWTx-002Var (Figure 4R). Cross-reactivity with cynomolgus monkey TMPRSS6 was observed with the MWTx-001 (Fig. 4K), MWTx-002 (Fig. 4M), and MWTx-003 (Fig. 4O) anti-TMPRSS6 antibodies and their humanized variants, hzMWTx-001Var (Fig. 4Q), hzMWTx-002Var (Fig. 4S), and hzMWTx-003Var (Fig. 4U) anti-TMPRSS6 antibodies.

[0090] Example 5: Target specificity: Anti-TMPRSS6 antibodies bind to homologous matriptase. To determine whether anti-TMPRSS6 antibodies bind to homologous matriptase, HEK293T cells overexpressing matriptase (ST14) (SEQ ID NO: 100) (Figures 5B, 5E, 5H, 5K, 5N, 5Q) and HEK293T cells overexpressing matriptase-3 (TMPRSS7) (SEQ ID NO: 101) (Figures 5C, 5F, 5I, 5L, 5O, 5R) were harvested (produced in-house). HEK293T cells stably expressing human TMPRSS6 (matriptase-2) (SEQ ID NO: 97) (generated by LakePharma Inc. as described above; Figures 5A, 5D, 5G, 5J, 5M, 5P) were used as a positive control, and HEK293T cells (Figures 5A-5R) were used as a negative control (as described above). Cells were blocked and permeabilized with dPBS + 3% BSA + 0.1% Tween-20 before incubation with various anti-TMPRSS6 antibodies diluted in dPBS + 3% BSA + 0.1% Tween-20. Cells were incubated with anti-TMPRSS6 antibodies and their humanized variants at approximately 1 μg / ml for 1 hour. After incubation, cells were washed with dPBS and incubated with either goat anti-mouse IgG conjugated to AlexaFluor-488 (Invitrogen, Figures 5A-5I) or goat anti-human IgG conjugated to allophycocyanin (APC) (Jackson Immuno Research, Figures 5J-5R) as the 2° antibody. Finally, cells were washed with dPBS, resuspended in dPBS + 1 mM EDTA, and then subjected to FACS analysis using a NOVOCYTE® Flow Cytometer. Bound antibodies were determined by excitation at 488 nm and measuring emission at 530 nm (FITC-A) (Figures 5A-5I) or by excitation at 640 nm and measuring emission at 675 nm (APC-A) (Figures 5J-5R). The results of these assays are shown in histogram plots in Figures 5A-5R. All antibodies showed binding to human TMPRSS6 (matriptase-2) (Figures 5A, 5D, 5G, 5J, 5M, 5P), and none of the antibodies showed binding to the homologous matriptase ST14 (Figures 5B, 5E, 5H, 5K, 5N, 5Q) or TMPRSS7 (Figures 5C, 5F, 5I, 5L, 5O, 5R).The MWTx-001 anti-TMPRSS6 antibody and its humanized variant hzMWTx-001Var anti-TMPRSS6 antibody showed binding to human TMPRSS6 (Figures 5A and 5J), but not to matriptase (ST14) (Figures 5B and 5K) or matriptase-3 (TMPRSS7) (Figures 5C and 5L). The MWTx-002 anti-TMPRSS6 antibody and its humanized variant hzMWTx-002Var anti-TMPRSS6 antibody showed binding to human TMPRSS6 (matriptase-2) (Figures 5D and 5M), but not to matriptase (ST14) (Figures 5E and 5N) or matriptase-3 (TMPRSS7) (Figures 5F and 5O). The MWTx-003 anti-TMPRSS6 antibody and its humanized variant hzMWTx-003Var anti-TMPRSS6 antibody showed binding to human TMPRSS6 (matriptase-2) (Figures 5G, 5P), but not to matriptase (ST14) (Figures 5H, 5Q) or matritase-3 (TMPRSS7) (Figures 5I, 5R).

[0091] Example 6: Treatment with anti-TMPRSS6 antibodies in a mouse pharmacodynamic model To study the in vivo pharmacodynamic response of anti-TMPRSS6 antibodies, 2–10 mg / kg of MWTx-003 anti-TMPRSS6 antibody (Figures 6A–6B, 6D–6E, 6G–6H, 6J–6K) or its humanized variant hzMWTx-003Var anti-TMPRSS6 antibody (Figures 6C, 6F, 6I, 6L) was intraperitoneally injected into wild-type C57BL / 6J mice. Mouse IgG2b (BioXcell, Figures 6A–6B, 6D–6E, 6G–6H, 6J–6K) or human IgG1 (BioXcell, Figures 6C, 6F, 6I, 6L) was used as an isotype control. Twenty hours after injection, 50 μg of GFP-TMPRSS6 plasmid DNA (in-house produced by inserting human TMPRSS6 into a GFP vector) was delivered to each mouse via hydrodynamic tail vein injection. Mice were euthanized 44 hours after hydrodynamic injection, and liver tissue and blood were collected. Liver RNA was purified using EZgene Total RNA Purification Plus from Biomiga (San Diego, CA) according to the manufacturer's instructions. Mouse serum was obtained by centrifugation of whole blood at 1500 × g for 10 minutes. Effect of anti-TMPRSS6 antibody treatment on serum iron

[0092] Serum iron was measured using a colorimetric assay developed in-house (Figures 6A-6C). Briefly, mouse serum or iron standards (31-500 μg / dL) were mixed with a mixed acid solution (0.6 M trichloroacetic acid, 0.4 M sodium thioglycolate, 1 M HCl) by vertexing for 30 seconds. The mixture was incubated at 37°C for 10 minutes, then centrifuged at 10,000 x g for 10 minutes and developed with Color Solution (1.5 M sodium acetate, 0.5 mM bathophenanthroline disulfonate). OD was then measured. 535nm Absorbance was read at 1000 kJ / min. Serum iron concentrations were calculated from a linear iron standard curve. Treatment with 10 mg / kg of the MWTx-003 anti-TMPRSS6 antibody (Figures 6A-6B) and its humanized variant, hzMWTx-003Var anti-TMPRSS6 antibody (Figure 6C), significantly reduced serum iron. Effect of anti-TMPRSS6 antibody treatment on serum hepcidin

[0093] Serum hepcidin was measured using a Hepcidin-Murine Compete ELISA kit purchased from Intrinsic Lifesciences (La Jolla, CA) according to the manufacturer's instructions (Figures 6D-6F). Briefly, diluted mouse serum or hepcidin standards were mixed with hepcidin-biotin conjugates and then added to plates coated with anti-mouse hepcidin antibodies. Serum hepcidin or hepcidin standards compete with the hepcidin-biotin conjugates and bind to the coated anti-hepcidin antibodies. Bound hepcidin-biotin conjugates were detected with streptavidin-conjugated horseradish peroxidase (HRP), developed with TMB, and stopped with stop solution. OD values ​​were then calculated. 450nm Absorbance was read at 100 kJ / min. Data were analyzed using a four-parameter logistic (4-PL) curve fit in Graphpad Prism 8, and serum hepcidin concentrations were interpolated. Hydrodynamic delivery of GFP-TMPRSS6 significantly reduced serum hepcidin concentrations (Figure 6D). However, treatment with 10 mg / kg of the MWTx-003 anti-TMPRSS6 antibody (Figures 6D-6E) and its humanized variant, hzMWTx-003Var anti-TMPRSS6 antibody (Figure 6F), reversed the suppression of hepcidin and significantly increased serum hepcidin concentrations. Effect of anti-TMPRSS6 antibody treatment on hepatic hepcidin RNA

[0094] Liver hepcidin RNA was quantified by real-time qPCR (Figures 6G–6I). Briefly, cDNA was first synthesized from liver RNA using iScript Reverse Transcription Supermix (Bio-Rad) according to the manufacturer's instructions. Hepcidin transcripts were amplified with specific primers listed in Table 4 and detected using SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad) according to the manufacturer's instructions on a Bio-Rad CFX96 qPCR instrument. Samples were analyzed in triplicate, and results were normalized to β-actin RNA levels (measured by transcription, amplification with the primers listed in Table 4, and quantification as described above). Hydrodynamic delivery of GFP-TMPRSS6 significantly reduced hepcidin RNA in the liver (Figure 6G). Treatment with 10 mg / kg of the MWTx-003 anti-TMPRSS6 antibody (Figures 6G-6H) and its humanized variant, hzMWTx-003Var anti-TMPRSS6 antibody (Figure 6I), reversed the suppression of Hamp and significantly increased hepcidin RNA levels in the liver. The following primers were used for RNA quantification by real-time qPCR: hepcidin forward primer: 5'-AAG CAG GGC AGA CAT TGC GAT-3' (SEQ ID NO: 85); hepcidin reverse primer: 5'-CAG GAT GTG GCT CTA GGC TAT-3' (SEQ ID NO: 86); β-actin forward primer: 5'-ACC CAC ACT GTG CCC ATC TA-3' (SEQ ID NO: 87); β-actin reverse primer: 5'-CAC GCT CGG TCA GGA TCT TC-3' (SEQ ID NO: 88).

[0095] Serum concentrations of the MWTx-003 anti-TMPRSS6 antibody or its humanized variant, hzMWTx-003Var anti-TMPRSS6 antibody, were quantified by an in-house developed cell surface ELISA (see Figures 6J-6L). Briefly, diluted mouse serum or anti-TMPRSS6 antibody standards were incubated with 100% methanol-fixed HEK293T cells stably expressing human TMPRSS6 (HEK293T cells served as a background control). Bound MWTx-003 anti-TMPRSS6 antibody was detected with goat anti-mouse IgG conjugated to HRP, and bound hzMWTx-003Var anti-TMPRSS6 antibody was detected with goat anti-human IgG conjugated to HRP. Color development was followed by quenching with TMB and stop solution. OD was then measured. 450nm Absorbance was read at 1000 kJ / min. Samples were analyzed in triplicate, and results were normalized to a HEK293T control. Data were analyzed using a four-parameter logistic (4-PL) curve fit in Graphpad Prism 8 to interpolate the anti-TMPRSS6 antibody concentration in serum.

[0096] Example 7: In vivo efficacy of anti-TMPRSS6 antibodies using a β-thalassemia mouse model To examine the in vivo effects of anti-TMPRSS6 antibodies, we used a mouse model of β-thalassemia (B6.129P2-Hbb-b1 tm1Unc Hbb-b2 tm1Unc We selected Th3 / + mice (J, JAX Stock No: 002683, The Jackson Laboratories, Bar Harbor, ME) and refer to them as Th3 / + mice in this study. Four- to five-week-old Th3 / + mice and their wild-type (WT) littermates were fed an iron-sufficient diet (Teklad TD.80394). Th3 / + mice were treated with 10 mg / kg MWTx-003 anti-TMPRSS6 antibody or mouse IgG2b isotype control every three days for four weeks, whereas WT littermates received no treatment. After the treatment course, mice were euthanized, and spleen, liver, femur, and blood samples were collected. Total RNA was purified from the liver, and serum was collected as described above.

[0097] Effects on blood counts, splenomegaly, serum iron, serum hepcidin, and liver hepcidin RNA Complete blood counts (CBCs) were performed using a VETSCAN HM5 automated blood cell counter (Figures 7A-7D). Treatment with the MWTx-003 anti-TMPRSS6 antibody significantly increased red blood cell counts (RBC, Figure 7A) and hematocrit (HCT, Figure 7C) and reduced red blood cell distribution width (RDW, Figure 7D) in Th3 / + mice, but had no significant effect on hemoglobin (HGB, Figure 7B).

[0098] Measurement of spleen weight revealed that treatment with MWTx-003 anti-TMPRSS6 antibody significantly suppressed spleen enlargement in Th3 / + mice ( Fig. 7E ).

[0099] Serum iron was measured as described above. Treatment with the MWTx-003 anti-TMPRSS6 antibody significantly reduced serum iron (Figure 7F). Liver non-heme iron was measured using a similar colorimetric assay (Figure 7G). Briefly, minced small liver tissue was dried overnight at 65°C and then digested with mixed acid (3 M HCl, 10% trichloroacetic acid) at 65°C for 20 hours. The digestion supernatant was then collected and developed with Color Solution (1.5 M sodium acetate, 0.5 mM bathophenanthroline disulfonate). OD was then measured. 535nm Absorbance was read at 1000 kJ / min. Treatment with MWTx-003 anti-TMPRSS6 antibody significantly reduced non-heme iron in the liver (Figure 7G).

[0100] Serum hepcidin was measured using a hepcidin-murine competent ELISA kit as described above. Treatment with MWTx-003 anti-TMPRSS6 antibody significantly increased serum hepcidin (Figure 7H).

[0101] Liver hepcidin RNA was quantified by real-time qPCR. Treatment with MWTx-003 anti-TMPRSS6 antibody significantly increased hepcidin RNA in the liver (Figure 7I).

[0102] Serum concentrations of MWTx-003 anti-TMPRSS6 antibody were quantified by an in-house developed cell surface ELISA as described above ( Figure 7J ). Effects on erythropoiesis

[0103] To examine the effect of the MWTx-003 anti-TMPRSS6 antibody on erythropoiesis in Th3 / + mice, bone marrow was harvested from the femur (see Figures 7K–7M) and splenocytes were harvested from the spleen (see Figures 7N–7P) and analyzed. Harvested cells were blocked with rat anti-mouse CD16 / CD32 (BD Biosciences) for 15 minutes, then stained with FITC-conjugated rat anti-mouse TER119 (BD Biosciences) and APC-conjugated rat anti-mouse CD44 (Invitrogen) for 30 minutes on ice. Washed cells were stained with the viability marker 7-AAD (BD Biosciences) for 10 minutes on ice before FACS analysis using a NOVOCYTE® Flow Cytometer. Ter119+, 7-ADD- cells were selected and plotted as a cell size vs. anti-mouse CD44 density plot (FSC-H). The plots were analyzed to identify cell types (cell clusters) and determine the abundance of each type (cluster). Representative plots in Figures 7K-7P show that four distinct cell clusters, corresponding to successive stages of erythroid differentiation, were distinguished from top to bottom and identified as follows: basophilic erythroblasts (cluster I), polychromatic erythroblasts (cluster II), normochromatic erythroblasts and anucleated reticulocytes (cluster III), and mature erythrocytes (cluster IV). As shown in Figures 7K-7P, the percentage (%) value of each cluster in a sample was calculated as an indicator of the abundance of a cell type within that cluster. For each sample (bone marrow, spleen) of each animal during each treatment course, the % values ​​of each cell cluster (I), (II), (III), and (IV) were calculated as follows: WT (untreated) N=9; disease model Th3 / + mice treated with IgG2b isotype control (Th3+w / MoIgG2b) N=5; disease model Th3 / + mice treated with MWTx-003 anti-TMPRSS6 antibody (Th3+w / MWTx-003) N=7. Mean values ​​were calculated.After 4 weeks in bone marrow cells, on average, basophilic erythroblasts (I) shifted from 7.58% (Th3+w / MoIgG2b) to 6.52% (Th3+w / MWTx-003) (7.96% vs. WT), polychromatic erythroblasts (II) shifted from 54.20% (Th3+w / MoIgG2b) to 40.01% (Th3+w / MWTx-003) (28.53% vs. WT), normochromatic erythroblasts and anucleated reticulocytes (III) shifted from 24.06% (Th3+w / MoIgG2b) to 29.73% (Th3+w / MWTx-003) (26.67% vs. WT), and mature erythrocytes (IV) shifted from 4.54% (Th3+w / MoIgG2b) to 16.44% (27.66% vs. WT). After 4 weeks in the spleen, on average, basophilic erythroblasts (I) shifted from 0.71% (Th3+w / MoIgG2b) to 0.91% (Th3+w / MWTx-003) (0.46% vs. WT), and polychromatic erythroblasts (II) shifted from 45.76% (Th3+w / MoIgG2b) to 19.25% (Th3+w / MWTx-003) (12.23% vs. WT). Normochromatic erythroblasts and nonnucleated reticulocytes (III) shifted from 31.16% (Th3+w / MoIgG2b) to 28.72% (Th3+w / MWTx-003) (8.67% compared to WT), and mature erythrocytes (IV) shifted from 14.13% (Th3+w / MoIgG2b) to 44.38% (Th3+w / MWTx-003) (72.17% compared to WT). These results are shown as bar graphs in Figure 7Q for bone marrow and Figure 7R for spleen, respectively.

[0104] In Th3 / + mice, treatment with the anti-TMPRSS6 antibody MWTx-003 reversed ineffective hematopoiesis, and a significant proportion of erythroblasts differentiated and matured into red blood cells.

[0105] Example 8: Anti-TMPRSS6 antibody epitope binning OCTET® RED96e was used for epitope binning of the MWTx-001 (Figure 8A), MWTx-002 (Figure 8B), and MWTx-003 (Figure 8C) anti-TMPRSS6 antibodies. First, ecto-TMPRSS6-FLAG (as described above) was labeled with biotin using a Biotinylation Kit (Abcam). A prehydrated streptavidin (SA) biosensor was equilibrated with 1x KB (as described above) for 60 seconds to establish a first baseline. Then, 10 mg / ml of biotinylated ecto-TMPRSS6-FLAG was loaded onto the SA biosensor for 300 seconds. A second baseline signal was then established for 60 seconds before saturation with 50 mg / ml of antibody in 1x KB (MWTx-001, Figure 8A; MWTx-002, Figure 8B; MWTx-003, Figure 8C). Finally, a third baseline signal was allowed to establish for 60 seconds before saturation with 50 μg / ml MWTx-001, MWTx-002, or MWTx-003 in 1xKB for 300 seconds. The binding of the MWTx-001 anti-TMPRSS6 antibody to ecto-TMPRSS6-FLAG was not competed with the MWTx-002 or MWTx-003 anti-TMPRSS6 antibodies (Figure 8A). The binding of the MWTx-002 anti-TMPRSS6 antibody to ecto-TMPRSS6-FLAG was not competed with the MWTx-001 anti-TMPRSS6 antibody, but was competed with the MWTx-003 anti-TMPRSS6 antibody (Figure 8B). The binding of the MWTx-003 anti-TMPRSS6 antibody to ecto-TMPRSS6-FLAG did not compete with that of the MWTx-001 anti-TMPRSS6 antibody, but did compete with that of the MWTx-002 anti-TMPRSS6 antibody (Figure 8C). Data analysis was performed using Octet Data Analysis HT Software. The association signals are summarized in Figure 8D.

Claims

1. An anti-type II transmembrane serine protease 6 (TMPRSS6) antibody comprising a heavy chain complementarity determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 52, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 54, and a light chain complementarity determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 57, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 58, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO:

59.

2. The antibody of claim 1 , wherein the antibody is a humanized antibody.

3. The antibody of claim 1 or 2, wherein the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 are grafted onto a framework comprising a variable region derived from a human immunoglobulin framework.

4. The antibody of any one of claims 1 to 3, comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:

51.

5. The antibody of any one of claims 1 to 4, comprising a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:

56.

6. The antibody of any one of claims 1 to 5, wherein the antibody is a full-length antibody, a Fab fragment, or a single-chain variable fragment (scFv).

7. The antibody of any one of claims 1 to 6, comprising an IgG1 heavy chain constant region.

8. The antibody of any one of claims 1 to 7, comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:

81.

9. The antibody of any one of claims 1 to 8, comprising a light chain comprising the amino acid sequence of SEQ ID NO:

83.

10. The antibody of any one of claims 1 to 9, which cross-reacts with at least one non-human TMPRSS6.

11. The antibody of claim 10, wherein the non-human TMPRSS6 is mouse TMPRSS6 or non-human primate TMPRSS6.

12. The antibody of any one of claims 1 to 11, which specifically binds to human TMPRSS6.

13. The antibody according to any one of claims 1 to 12, which does not specifically bind to human matriptase-1 or human matriptase-3.

14. A composition comprising the antibody of any one of claims 1 to 13.

15. 15. The composition of claim 14, further comprising a pharmaceutically acceptable carrier.

16. An isolated nucleic acid encoding the heavy chain variable region and the light chain variable region of the antibody of any one of claims 1 to 13.

17. 17. The isolated nucleic acid of claim 16, comprising the nucleic acid sequence of SEQ ID NO: 55 and the nucleic acid sequence of SEQ ID NO:

60.

18. An isolated nucleic acid encoding the heavy and light chains of the antibody of any one of claims 1 to 13.

19. 19. The isolated nucleic acid of claim 18, comprising the sequence of SEQ ID NO: 82 and the nucleic acid sequence of SEQ ID NO:

84.

20. A vector comprising the isolated nucleic acid of any one of claims 16 to 19.

21. A host cell comprising the vector of claim 20.

Images